<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="li-fraumeni" content-type="chapter" from-where="body" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">gene</book-id>
    <book-title-group>
      <book-title>GeneReviews<sup>&#x000ae;</sup></book-title>
    </book-title-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Adam</surname>
          <given-names>Margaret P</given-names>
        </name>
        <role>Editor-in-Chief</role>
      </contrib>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ardinger</surname>
          <given-names>Holly H</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Pagon</surname>
          <given-names>Roberta A</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Wallace</surname>
          <given-names>Stephanie E</given-names>
        </name>
      </contrib>
      <role>Senior Editors</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Bean</surname>
          <given-names>Lora JH</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Mefford</surname>
          <given-names>Heather C</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Stephens</surname>
          <given-names>Karen</given-names>
        </name>
      </contrib>
      <role>Molecular Genetics</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Amemiya</surname>
          <given-names>Anne</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ledbetter</surname>
          <given-names>Nikki</given-names>
        </name>
      </contrib>
      <role>Genetic Counseling</role>
    </contrib-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>1993</year>
    </pub-date>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>2017</year>
    </pub-date>
    <issn>2372-0697</issn>
    <publisher>
      <publisher-name>University of Washington, Seattle</publisher-name>
      <publisher-loc>Seattle (WA)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 1993-2017, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved.</copyright-statement>
      <copyright-year>2017</copyright-year>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK138602/">
        <license-p>GeneReviews&#x000ae; chapters are owned by the University of Washington. Permission is hereby granted to reproduce, distribute, and translate copies of content materials for noncommercial research purposes only, provided that (i) credit for source (<ext-link ext-link-type="uri" xlink:href="http://www.genereviews.org/">http://www.genereviews.org/</ext-link>) and copyright (&#x000a9; 1993-2017 University of Washington) are included with each copy; (ii) a link to the original material is provided whenever the material is published elsewhere on the Web; and (iii) reproducers, distributors, and/or translators comply with the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>. No further modifications are allowed. For clarity, excerpts of GeneReviews chapters for use in lab reports and clinic notes are a permitted use.</license-p>
        <license-p>For more information, see the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>.</license-p>
        <license-p>For questions regarding permissions or whether a specified use is allowed, contact: <email>admasst@uw.edu</email>.</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Genetics</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Medicine</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Diseases</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="ednotes">
      <p content-type="genetic_counseling">
<italic toggle="yes">Genetic counseling is the process of
providing individuals and families with information on the nature, inheritance,
and implications of genetic disorders to help them make informed medical and
personal decisions. The following section deals with genetic risk assessment and
the use of family history and genetic testing to clarify genetic status for
family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with
a genetics professional</italic>. &#x02014;ED.</p>
      <p content-type="resources">
<italic toggle="yes">GeneReviews staff has selected the following disease-specific and/or
umbrella support organizations and/or registries for the benefit of individuals
with this disorder and their families. GeneReviews is not responsible for the
information provided by other organizations. For information on selection
criteria, click <related-object source-id="gene" document-id="app4">here</related-object>.</italic></p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <book-part-id book-part-id-type="pmcid">li-fraumeni</book-part-id>
      <title-group>
        <title>Li-Fraumeni Syndrome</title>
        <alt-title alt-title-type="alt-title">Synonym: SBLA Syndrome (Sarcoma, Breast, Leukemia, and Adrenal Gland)</alt-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Schneider</surname>
            <given-names>Katherine</given-names>
          </name>
          <degrees>MPH</degrees>
          <aff>Adult Oncology <break/>Dana Farber Cancer Institute <break/>Boston, Massachusetts</aff>
          <email>katherine_schneider@dfci.harvard.edu</email>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Zelley</surname>
            <given-names>Kristin</given-names>
          </name>
          <degrees>MS</degrees>
          <aff>Children&#x02019;s Hospital of Philadelphia<break/>Philadelphia, Pennsylvania</aff>
          <email>zelleyk@email.chop.edu</email>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Nichols</surname>
            <given-names>Kim E</given-names>
          </name>
          <degrees>MD</degrees>
          <aff>Children&#x02019;s Hospital of Philadelphia<break/>Philadelphia, Pennsylvania</aff>
          <email>nicholsk@email.chop.edu</email>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Garber</surname>
            <given-names>Judy</given-names>
          </name>
          <degrees>MD, MPH</degrees>
          <aff>Adult Oncology <break/>Dana Farber Cancer Institute <break/>Boston, Massachusetts</aff>
          <email>judy_garber@dfci.harvard.edu</email>
        </contrib>
      </contrib-group>
      <pub-history>
        <date iso-8601-date="1999-01-19" date-type="created">
          <day>19</day>
          <month>1</month>
          <year>1999</year>
        </date>
        <date iso-8601-date="2013-04-11" date-type="updated">
          <day>11</day>
          <month>4</month>
          <year>2013</year>
        </date>
      </pub-history>
      <related-object link-type="parent-book-link" source-id="gene">GeneReviews<sup>&#x000ae;</sup></related-object>
      <related-object link-type="previous-part-link" source-id="gene" document-id="lbsl" document-type="chapter">Leukoencephalopathy with Brain Stem and Spinal Cord Involvement and Lactate Elevation</related-object>
      <related-object link-type="next-part-link" source-id="gene" document-id="lgmd-overview" document-type="chapter">Limb-Girdle Muscular Dystrophy Overview</related-object>
      <abstract id="li-fraumeni.Summary">
        <title>Summary</title>
        <sec>
          <title>Clinical characteristics</title>
          <p>Li-Fraumeni syndrome (LFS) is a cancer predisposition syndrome associated with the development of the following classic tumors: soft tissue sarcoma, osteosarcoma, pre-menopausal breast cancer, brain tumors, adrenocortical carcinoma (ACC), and leukemias. In addition, a variety of other neoplasms may occur. LFS-related cancers often occur in childhood or young adulthood and survivors have an increased risk for multiple primary cancers. Age-specific cancer risks have been calculated.</p>
        </sec>
        <sec>
          <title>Diagnosis/testing</title>
          <p>LFS is diagnosed in individuals meeting established clinical criteria or in those who have a germline pathogenic variant in <italic toggle="yes">TP53</italic> regardless of family cancer history. At least 70% of individuals diagnosed clinically have an identifiable germline pathogenic variant in <italic toggle="yes">TP53,</italic> the only gene so far identified in which mutation is definitively associated with LFS.</p>
        </sec>
        <sec>
          <title>Management</title>
          <p><italic toggle="yes">Treatment of manifestations:</italic> Routine oncologic management is recommended for malignancies in individuals with LFS, with the exception of breast cancer, in which mastectomy rather than lumpectomy is recommended in order to reduce the risks of a second primary breast tumor and avoid radiation therapy. Concerns about increased risk for radiation-induced second primary tumors has led to more cautious use of therapeutic radiation in general, but most experts recommend that treatment efficacy be prioritized above concerns about late effects after careful analysis of risks and benefits.</p>
          <p><italic toggle="yes">Prevention of primary manifestations:</italic> Prophylactic mastectomy to reduce the risk for breast cancer is an option for women with a germline <italic toggle="yes">TP53</italic> pathogenic variant. Recent recommendations for colonoscopy may be considered surveillance as well as primary prevention of colorectal cancer.</p>
          <p><italic toggle="yes">Prevention of secondary complications:</italic> Avoidance of exposure to radiation therapy, when possible, to reduce the risk of secondary radiation-induced malignancies.</p>
          <p><italic toggle="yes">Surveillance:</italic> There are no definitive prospective data on the optimal methods for and efficacy of tumor surveillance for children or adults with a germline <italic toggle="yes">TP53</italic> pathogenic variant. Currently, it is recommended that: (1) children and adults undergo comprehensive annual physical examination; (2) children and adults be encouraged see a physician promptly for evaluation of lingering symptoms and illnesses; (3) women undergo breast cancer monitoring, with annual breast MRI and twice annual clinical breast examination beginning at age 20-25 years. The use of mammograms has been controversial because of radiation exposure and limited sensitivity. When included, annual mammograms should alternate with breast MRI, with one modality every six months; (4) adults consider routine screening for colorectal cancer with colonoscopy every 2-3 years beginning no later than age 25 years; (5) individuals consider organ-targeted surveillance based on the pattern of cancer observed in their family. Intensified surveillance with whole-body MRI protocols for adults and children who carry a germline <italic toggle="yes">TP53</italic> pathogenic variant are being evaluated in investigational settings.</p>
          <p><italic toggle="yes">Agents/circumstances to avoid:</italic> People with germline <italic toggle="yes">TP53</italic> pathogenic variants should: (1) avoid known carcinogens including sun exposure, tobacco use, occupational exposures, and excessive alcohol use; and (2) minimize exposure to diagnostic and therapeutic radiation.</p>
          <p><italic toggle="yes">Evaluation of relatives at risk:</italic> It is appropriate to offer genetic counseling and testing to all relatives who are at risk of having a familial <italic toggle="yes">TP53</italic> pathogenic variant.</p>
        </sec>
        <sec>
          <title>Genetic counseling</title>
          <p>LFS is inherited in an autosomal dominant manner. The proportion of individuals with a <italic toggle="yes">de nov</italic>o germline <italic toggle="yes">TP53</italic> pathogenic variant is estimated to be between 7% and 20%. Offspring of an affected individual have a 50% chance of inheriting the deleterious allelic variant. Predisposition testing for at-risk family members and prenatal testing for pregnancies at increased risk are possible if the heritable pathogenic variant in the family has been identified.</p>
        </sec>
      </abstract>
    </book-part-meta>
    <body>
      <sec id="li-fraumeni.Diagnosis">
        <title>Diagnosis</title>
        <sec id="li-fraumeni.Clinical_Diagnosis">
          <title>Clinical Diagnosis</title>
          <p><bold>Classic Li-Fraumeni syndrome (LFS)</bold> is defined by presence of <bold>all</bold> of the following criteria:</p>
          <list list-type="bullet">
            <list-item>
              <p>A proband with a sarcoma diagnosed before age 45 years</p>
            </list-item>
            <list-item>
              <p>A first-degree relative with any cancer before age 45 years</p>
            </list-item>
            <list-item>
              <p>A first- or second-degree relative with any cancer before age 45 years or a sarcoma at any age [<xref ref-type="bibr" rid="li-fraumeni.REF.li.1988.5358">Li et al 1988</xref>]</p>
            </list-item>
          </list>
          <p>The diagnosis of LFS should also be suspected in individuals with the following:</p>
          <list list-type="bullet">
            <list-item>
              <p><bold>Any individual who meets the Chompret criteria for <italic toggle="yes">TP53</italic> testing.</bold> It is estimated that at least 20% of individuals who meet the Chompret criteria have a detectable <italic toggle="yes">TP53</italic> pathogenic variant [<xref ref-type="bibr" rid="li-fraumeni.REF.chompret.2001.43">Chompret et al 2001</xref>]. More recent series have shown that 92%-95% of individuals who tested positive for germline <italic toggle="yes">TP53</italic> pathogenic variants met the revised Chompret criteria for LFS [<xref ref-type="bibr" rid="li-fraumeni.REF.gonzalez.2009b.1250">Gonzalez et al 2009b</xref>, <xref ref-type="bibr" rid="li-fraumeni.REF.tinat.2009.e108">Tinat et al 2009</xref>, <xref ref-type="bibr" rid="li-fraumeni.REF.ruijs.2010.421">Ruijs et al 2010</xref>]:</p>
              <list list-type="bullet">
                <list-item>
                  <p>Proband with a tumor belonging to the LFS tumor spectrum (e.g. soft tissue sarcoma, osteosarcoma, brain tumor, pre-menopausal breast cancer, adrenocortical carcinoma, leukemia, lung bronchoalveolar cancer) before age 46 years AND at least one first- or second-degree relative with a LFS tumor (except breast cancer if the proband has breast cancer) before age 56 years or with multiple tumors; OR</p>
                </list-item>
                <list-item>
                  <p>Proband with multiple tumors (except multiple breast tumors), two of which belong to the LFS tumor spectrum and the first of which occurred before age 46 years; OR</p>
                </list-item>
                <list-item>
                  <p>Proband with adrenocortical carcinoma or choroid plexus tumor, regardless of family history</p>
                </list-item>
              </list>
            </list-item>
            <list-item>
              <p><bold>Any woman who has a personal history of early-onset breast cancer and does not have an identifiable <italic toggle="yes">BRCA1</italic> or <italic toggle="yes">BRCA2</italic> pathogenic variant.</bold> A woman who is diagnosed with breast cancer before age 30 years and is not found to have a pathogenic <italic toggle="yes">BRCA</italic> variant has an estimated 4%-8% likelihood of having a <italic toggle="yes">TP53</italic> pathogenic variant [<xref ref-type="bibr" rid="li-fraumeni.REF.gonzalez.2009b.1250">Gonzalez et al 2009b</xref>, <xref ref-type="bibr" rid="li-fraumeni.REF.mouchawar.2010.4795">Mouchawar et al 2010</xref>, <xref ref-type="bibr" rid="li-fraumeni.REF.mccuaig.2012.607">McCuaig et al 2012</xref>]. Women with breast cancer diagnosed between ages 30 and 39 years may also have a small increased risk of having a <italic toggle="yes">TP53</italic> pathogenic variant [<xref ref-type="bibr" rid="li-fraumeni.REF.lee.2012.r66">Lee et al 2012</xref>].</p>
              <list list-type="bullet">
                <list-item>
                  <p>The likelihood of a <italic toggle="yes">TP53</italic> pathogenic variant in women with early-onset breast cancer is further increased if any of the following are also present:</p>
                  <list list-type="bullet">
                    <list-item>
                      <p>A family history of cancer, especially LFS-related cancers [<xref ref-type="bibr" rid="li-fraumeni.REF.tinat.2009.e108">Tinat et al 2009</xref>, <xref ref-type="bibr" rid="li-fraumeni.REF.mccuaig.2012.607">McCuaig et al 2012</xref>]</p>
                    </list-item>
                    <list-item>
                      <p>A personal history of a breast tumor that is positive for estrogen, progesterone, and/or Her2/neu markers [<xref ref-type="bibr" rid="li-fraumeni.REF.masciari.2012.1125">Masciari et al 2012</xref>, <xref ref-type="bibr" rid="li-fraumeni.REF.melhembertrandt.2012.908">Melhem-Bertrandt et al 2012</xref>]</p>
                    </list-item>
                    <list-item>
                      <p>A personal history of an additional LFS-related cancer [<xref ref-type="bibr" rid="li-fraumeni.REF.tinat.2009.e108">Tinat et al 2009</xref>]</p>
                    </list-item>
                  </list>
                </list-item>
              </list>
            </list-item>
            <list-item>
              <p><bold>Any individual who has a personal history of adrenocortical carcinoma (ACC), regardless of family histor<italic toggle="yes">y.</italic></bold> The likelihood of a <italic toggle="yes">TP53</italic> pathogenic variant is 50%-80% for children with ACC even in the absence of further family history [<xref ref-type="bibr" rid="li-fraumeni.REF.varley.1999.995">Varley et al 1999</xref>, <xref ref-type="bibr" rid="li-fraumeni.REF.lib_.2005.477">Lib&#x000e9; &#x00026; Bertherat 2005</xref>].</p>
              <list list-type="bullet">
                <list-item>
                  <p><italic toggle="yes">TP53</italic> pathogenic variants may also occur in individuals with adult-onset ACC [<xref ref-type="bibr" rid="li-fraumeni.REF.gonzalez.2009b.1250">Gonzalez et al 2009b</xref>]. In one series, 5.8% of individuals with adult-onset ACC were found to have a pathogenic <italic toggle="yes">TP53</italic> variant [<xref ref-type="bibr" rid="li-fraumeni.REF.raymond.2013.e119">Raymond et al 2013</xref>]. However, the likelihood of a <italic toggle="yes">TP53</italic> pathogenic variant is lower if ACC is diagnosed in an individual older than age 40 [<xref ref-type="bibr" rid="li-fraumeni.REF.herrmann.2012.e476">Herrmann et al 2012</xref>].</p>
                </list-item>
                <list-item>
                  <p>Another study evaluated the correlation between somatic and germline <italic toggle="yes">TP53</italic> pathogenic variants in individuals with ACC. Researchers identified aberrant p53 expression in 40% of ACC tumors. Furthermore, 25% of the individuals in the cohort with aberrant p53 expression were ultimately found to have germline <italic toggle="yes">TP53</italic> pathogenic variants [<xref ref-type="bibr" rid="li-fraumeni.REF.waldmann.2012.209">Waldmann et al 2012</xref>].</p>
                </list-item>
              </list>
            </list-item>
            <list-item>
              <p><bold>Any individual who has a personal history of choroid plexus carcinoma (CPC), regardless of family history<italic toggle="yes">.</italic></bold> Children with this rare type of brain tumor appear to have a high likelihood of having a <italic toggle="yes">TP53</italic> pathogenic variant even in the absence of further family history.</p>
              <list list-type="bullet">
                <list-item>
                  <p>In one series, all nine individuals with a personal or family history of CPC had a germline <italic toggle="yes">TP53</italic> pathogenic variant [<xref ref-type="bibr" rid="li-fraumeni.REF.gonzalez.2009b.1250">Gonzalez et al 2009b</xref>].</p>
                </list-item>
                <list-item>
                  <p>In another small series, 36.4% of children with CPC tested positive for a <italic toggle="yes">TP53</italic> pathogenic variant [<xref ref-type="bibr" rid="li-fraumeni.REF.gozali.2012.905">Gozali et al 2012</xref>].</p>
                </list-item>
              </list>
            </list-item>
          </list>
        </sec>
        <sec id="li-fraumeni.Molecular_Genetic_Testing">
          <title>Molecular Genetic Testing</title>
          <p><bold>Genes.</bold>
<italic toggle="yes">TP53</italic> is the only gene in which mutation is known to cause LFS [<xref ref-type="bibr" rid="li-fraumeni.REF.malkin.2011.475">Malkin 2011</xref>].</p>
          <p>About 80% of families with features of LFS have an identifiable <italic toggle="yes">TP53</italic> pathogenic variant. Families who have no identifiable <italic toggle="yes">TP53</italic> pathogenic variants yet share certain clinical features of LFS are more likely to have a different hereditary cancer syndrome (see <xref ref-type="sec" rid="li-fraumeni.Differential_Diagnosis">Differential Diagnosis</xref>).</p>
          <p>
            <bold>Clinical testing</bold>
          </p>
          <table-wrap id="li-fraumeni.T.summary_of_molecular_genet" position="anchor" orientation="portrait">
            <label>Table 1. </label>
            <caption>
              <p>Summary of Molecular Genetic Testing Used in Li-Fraumeni Syndrome</p>
            </caption>
            <table frame="hsides" rules="groups">
              <thead>
                <tr>
                  <th id="hd_h_li-fraumeni.T.summary_of_molecular_genet_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Gene&#x000a0;<sup>1</sup></th>
                  <th id="hd_h_li-fraumeni.T.summary_of_molecular_genet_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Test Method</th>
                  <th id="hd_h_li-fraumeni.T.summary_of_molecular_genet_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Allelic Variants Detected&#x000a0;<sup>2</sup></th>
                  <th id="hd_h_li-fraumeni.T.summary_of_molecular_genet_1_1_1_4" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Mutation Detection Frequency by Test Method&#x000a0;<sup>3,&#x000a0;4</sup></th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td headers="hd_h_li-fraumeni.T.summary_of_molecular_genet_1_1_1_1" rowspan="3" valign="middle" align="left" scope="row" colspan="1">
                    <italic toggle="yes">TP53</italic>
                  </td>
                  <td headers="hd_h_li-fraumeni.T.summary_of_molecular_genet_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Sequence analysis</td>
                  <td headers="hd_h_li-fraumeni.T.summary_of_molecular_genet_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Sequence variants&#x000a0;<sup>5</sup></td>
                  <td headers="hd_h_li-fraumeni.T.summary_of_molecular_genet_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">~95%&#x000a0;<sup>6,&#x000a0;7</sup></td>
                </tr>
                <tr>
                  <td headers="hd_h_li-fraumeni.T.summary_of_molecular_genet_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Sequence analysis of select exons&#x000a0;<sup>8</sup></td>
                  <td headers="hd_h_li-fraumeni.T.summary_of_molecular_genet_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Sequence variants&#x000a0;<sup>5</sup> only in the select exons</td>
                  <td headers="hd_h_li-fraumeni.T.summary_of_molecular_genet_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Unknown</td>
                </tr>
                <tr>
                  <td headers="hd_h_li-fraumeni.T.summary_of_molecular_genet_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Deletion/duplication analysis&#x000a0;<sup>9</sup></td>
                  <td headers="hd_h_li-fraumeni.T.summary_of_molecular_genet_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Deletions involving the coding region, exon 1, or promoter</td>
                  <td headers="hd_h_li-fraumeni.T.summary_of_molecular_genet_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">~1%&#x000a0;<sup>10</sup></td>
                </tr>
              </tbody>
            </table>
            <table-wrap-foot>
              <fn id="li-fraumeni.TF.1.1">
                <label>1. </label>
                <p>See <related-object source-id="gene" document-id="li-fraumeni" object-id="li-fraumeni.molgen.TA">Table A. Genes and Databases</related-object> for chromosome locus and protein.</p>
              </fn>
              <fn id="li-fraumeni.TF.1.2">
                <label>2. </label>
                <p>See <xref ref-type="sec" rid="li-fraumeni.Molecular_Genetics">Molecular Genetics</xref> for information on allelic variants.</p>
              </fn>
              <fn id="li-fraumeni.TF.1.3">
                <label>3. </label>
                <p>The ability of the test method used to detect a pathogenic variant that is present in the indicated gene.</p>
              </fn>
              <fn id="li-fraumeni.TF.1.4">
                <label>4. </label>
                <p>In the approximately 80% of families with a detectable pathogenic variant</p>
              </fn>
              <fn id="li-fraumeni.TF.1.5">
                <label>5. </label>
                <p>Examples of variants detected by sequence analysis may include small intragenic deletions/insertions and missense, nonsense, and splice site variants; typically, exon or whole-gene deletions/duplications are not detected. For issues to consider in interpretation of sequence analysis results, click <related-object link-type="booklink" source-id="gene" document-id="app2" document-type="appendix">here</related-object>.</p>
              </fn>
              <fn id="li-fraumeni.TF.1.6">
                <label>6. </label>
                <p>Sequence analysis of the entire <italic toggle="yes">TP53</italic> coding region (exons 2-11) detects about 95% of <italic toggle="yes">TP53</italic> pathogenic variants, most of which are missense variants. It is estimated that about 80% of individuals with LFS have detectable <italic toggle="yes">TP53</italic> pathogenic variants [<xref ref-type="bibr" rid="li-fraumeni.REF.malkin.2011.475">Malkin 2011</xref>].</p>
              </fn>
              <fn id="li-fraumeni.TF.1.7">
                <label>7. </label>
                <p>The frequency of <italic toggle="yes">de novo</italic> pathogenic variants in LFS is between 7% and 20% [<xref ref-type="bibr" rid="li-fraumeni.REF.gonzalez.2009a.689">Gonzalez et al 2009a</xref>].</p>
              </fn>
              <fn id="li-fraumeni.TF.1.8">
                <label>8. </label>
                <p>Select exons may vary by laboratory.</p>
              </fn>
              <fn id="li-fraumeni.TF.1.9">
                <label>9. </label>
                <p>Testing that identifies deletions/duplications not readily detectable by sequence analysis of the coding and flanking intronic regions of genomic DNA; included in the variety of methods that may be used are: quantitative PCR, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and chromosomal microarray (CMA) that includes this gene/chromosome segment.</p>
              </fn>
              <fn id="li-fraumeni.TF.1.10">
                <label>10. </label>
                <p>Classic LFS can also be caused by a deletion involving the coding region of <italic toggle="yes">TP53</italic> or the promoter and non-coding exon 1. Several reports of <italic toggle="yes">TP53</italic> genomic rearrangements in families with LFS indicate that this type of pathogenic variant may account for about 1% of LFS cases [<xref ref-type="bibr" rid="li-fraumeni.REF.bougeard.2003.840">Bougeard et al 2003</xref>, <xref ref-type="bibr" rid="li-fraumeni.REF.gonzalez.2009b.1250">Gonzalez et al 2009b</xref>].</p>
              </fn>
            </table-wrap-foot>
          </table-wrap>
          <p>
            <bold>Interpretation of test results</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>Duplications, inversions, large deletions, and pathogenic variants in noncoding regions are not likely to be detected by genomic sequence analysis [<xref ref-type="bibr" rid="li-fraumeni.REF.bougeard.2003.840">Bougeard et al 2003</xref>].</p>
            </list-item>
            <list-item>
              <p>A functional assay may be useful in determining the clinical significance of novel pathogenic missense variants [<xref ref-type="bibr" rid="li-fraumeni.REF.yamada.2009.973">Yamada et al 2009</xref>], although such testing is only performed in specific research laboratories.</p>
            </list-item>
          </list>
        </sec>
        <sec id="li-fraumeni.Testing_Strategy">
          <title>Testing Strategy</title>
          <p><bold>To confirm/establish the diagnosis in a proband.</bold> The diagnosis of LFS is confirmed by the presence of a germline pathogenic variant in <italic toggle="yes">TP53</italic>.</p>
          <list list-type="bullet">
            <list-item>
              <p>Unless a specific pathogenic variant has been identified in the family, <italic toggle="yes">TP53</italic> testing should be comprehensive and include both sequence and deletion/duplication analyses.</p>
            </list-item>
          </list>
          <p><bold>Predictive testing</bold> for at-risk asymptomatic family members requires prior identification of the germline <italic toggle="yes">TP53</italic> pathogenic variant in the family.</p>
          <p><bold>Prenatal diagnosis and preimplantation genetic diagnosis (PGD)</bold> for at-risk pregnancies require prior identification of the germline <italic toggle="yes">TP53</italic> pathogenic variant in the family.</p>
        </sec>
      </sec>
      <sec id="li-fraumeni.Clinical_Characteristics">
        <title>Clinical Characteristics</title>
        <sec id="li-fraumeni.Clinical_Description">
          <title>Clinical Description</title>
          <p><bold>Core cancers.</bold> Li-Fraumeni syndrome (LFS) is associated with high risks of a diverse spectrum of childhood- and adult-onset malignancies [<xref ref-type="bibr" rid="li-fraumeni.REF.nichols.2001.83">Nichols et al 2001</xref>, <xref ref-type="bibr" rid="li-fraumeni.REF.olivier.2003.6643">Olivier et al 2003</xref>, <xref ref-type="bibr" rid="li-fraumeni.REF.lindor.2008">Lindor et al 2008</xref>].</p>
          <p>The tumors most closely associated with LFS are: soft tissue sarcoma, osteosarcoma, pre-menopausal breast cancer, brain tumors, and adrenocortical carcinoma. These core cancers, which are described below, account for about 70% of all LFS-related tumors [<xref ref-type="bibr" rid="li-fraumeni.REF.olivier.2003.6643">Olivier et al 2003</xref>, <xref ref-type="bibr" rid="li-fraumeni.REF.gonzalez.2009b.1250">Gonzalez et al 2009b</xref>, <xref ref-type="bibr" rid="li-fraumeni.REF.ruijs.2010.421">Ruijs et al 2010</xref>]:</p>
          <list list-type="bullet">
            <list-item>
              <p><bold>Sarcomas.</bold> Individuals with LFS are at increased risk of developing soft tissue and bone sarcomas. The International Agency for Research on Cancer (IARC) <italic toggle="yes">TP53</italic> database found that sarcomas represented 25% of the cancers reported in people with LFS. The most commonly occurring sarcomas in the IARC <italic toggle="yes">TP53</italic> database were rhabdomyosarcomas before age five years and osteosarcomas at any age. Other forms of sarcoma included leiomyosarcomas, liposarcomas, and histiosarcomas; 16 other histology types were also noted [<xref ref-type="bibr" rid="li-fraumeni.REF.ognjanovic.2012.1387">Ognjanovic et al 2012</xref>]. LFS-related sarcomas can occur in childhood or adulthood, with most LFS-associated sarcomas occurring before age 50 years. Sarcomas that were not reported in the IARC <italic toggle="yes">TP53</italic> database, and are less likely to be features of LFS, include gastrointestinal stromal tumors, desmoid tumors/fibromatosis, Ewing sarcomas, and angiosarcomas [<xref ref-type="bibr" rid="li-fraumeni.REF.ognjanovic.2012.1387">Ognjanovic et al 2012</xref>].</p>
            </list-item>
            <list-item>
              <p><bold>Breast cancer.</bold> Women with LFS are at greatly increased risk of developing pre-menopausal breast cancer. The median age of breast cancer diagnosis in women with LFS is about 33 years [<xref ref-type="bibr" rid="li-fraumeni.REF.olivier.2003.6643">Olivier et al 2003</xref>]. In one series of women with LFS-related breast cancers, 32% of the cancers occurred before age 30 years and none of the breast cancers occurred after age 50 years [<xref ref-type="bibr" rid="li-fraumeni.REF.birch.1994.1298">Birch et al 1994</xref>]. Recent data suggest that LFS-related breast cancers are predominantly positive by immunohistochemistry and FISH (for HER2/neu) for hormone receptors and/or Her2/neu [<xref ref-type="bibr" rid="li-fraumeni.REF.wilson.2010.771">Wilson et al 2010</xref>, <xref ref-type="bibr" rid="li-fraumeni.REF.masciari.2012.1125">Masciari et al 2012</xref>, <xref ref-type="bibr" rid="li-fraumeni.REF.melhembertrandt.2012.908">Melhem-Bertrandt et al 2012</xref>]. In one series, 84% of the LFS-related breast tumors were positive for estrogen and/or progesterone hormone markers, and 63% of the invasive breast cancers and 73% of <italic toggle="yes">in situ</italic> breast cancers were Her2/neu positive [<xref ref-type="bibr" rid="li-fraumeni.REF.masciari.2012.1125">Masciari et al 2012</xref>]. In another study, 67% of the LFS-related breast cancers were Her2/neu positive compared to 25% of the controls [<xref ref-type="bibr" rid="li-fraumeni.REF.melhembertrandt.2012.908">Melhem-Bertrandt et al 2012</xref>]. Malignant phyllodes tumors of the breast may also be associated with LFS [<xref ref-type="bibr" rid="li-fraumeni.REF.birch.2001.4621">Birch et al 2001</xref>]. To date, male breast cancer has rarely been reported in families with LFS.</p>
            </list-item>
            <list-item>
              <p><bold>Brain tumors.</bold> Individuals with LFS are at increased risk of developing many types of brain tumors (e.g., astrocytomas, glioblastomas, medulloblastomas, choroid plexus carcinomas [CPC]). LFS-related brain tumors can occur in childhood or adulthood; the median age of onset is 16 years [<xref ref-type="bibr" rid="li-fraumeni.REF.olivier.2003.6643">Olivier et al 2003</xref>]. The likelihood of germline <italic toggle="yes">TP53</italic> pathogenic variants in children with CPC is high, even in the absence of a family history suggestive of LFS [<xref ref-type="bibr" rid="li-fraumeni.REF.krutilkova.2005.1597">Krutilkova et al 2005</xref>, <xref ref-type="bibr" rid="li-fraumeni.REF.tabori.2010.1995">Tabori et al 2010</xref>]. A rare peripheral nerve sheath tumor termed malignant triton tumor has also been reported in a child with a germline <italic toggle="yes">TP53</italic> pathogenic variant [<xref ref-type="bibr" rid="li-fraumeni.REF.chao.2007.1000">Chao et al 2007</xref>]. Malignant triton tumors contain schwannoma cells and rhabdomyoblasts.</p>
            </list-item>
            <list-item>
              <p><bold>Adrenocortical carcinomas (ACC)</bold>. Individuals with LFS are at increased risk of developing ACC. Children with ACC have a 50%-80% chance of having a germline <italic toggle="yes">TP53</italic> pathogenic variant, even in the absence of additional family history [<xref ref-type="bibr" rid="li-fraumeni.REF.lib_.2005.477">Lib&#x000e9; &#x00026; Bertherat 2005</xref>, <xref ref-type="bibr" rid="li-fraumeni.REF.gonzalez.2009b.1250">Gonzalez et al 2009b</xref>]. Individuals with adult-onset ACC may also be at increased risk for a germline <italic toggle="yes">TP53</italic> pathogenic variant, especially if diagnosed before age 50 years [<xref ref-type="bibr" rid="li-fraumeni.REF.gonzalez.2009b.1250">Gonzalez et al 2009b</xref>]. In one series, 5.8% of individuals diagnosed with ACC after age 18 years tested positive for a germline <italic toggle="yes">TP53</italic> pathogenic variant [<xref ref-type="bibr" rid="li-fraumeni.REF.raymond.2013.e119">Raymond et al 2013</xref>].</p>
            </list-item>
          </list>
          <p><bold>Excess of early-onset cancers.</bold> Individuals with LFS are at increased risk of developing cancer at younger than typical ages. It is estimated that 50% of LFS-associated malignancies occur by age 30 years [<xref ref-type="bibr" rid="li-fraumeni.REF.lustbader.1992.344">Lustbader et al 1992</xref>]. In one series of individuals who have a germline <italic toggle="yes">TP53</italic> pathogenic variant, the median age at diagnosis was 25 years [<xref ref-type="bibr" rid="li-fraumeni.REF.gonzalez.2009b.1250">Gonzalez et al 2009b</xref>].</p>
          <p>When assessing the likelihood that a family could have LFS, the age at diagnosis is important [<xref ref-type="bibr" rid="li-fraumeni.REF.nichols.2001.83">Nichols et al 2001</xref>]. For example, one series found that in six individuals with germline <italic toggle="yes">TP53</italic> pathogenic variants who had developed colorectal cancer, four occurred before age 21 years [<xref ref-type="bibr" rid="li-fraumeni.REF.wong.2006.73">Wong et al 2006</xref>]. Therefore, in assessing families with possible LFS, an unusually young age at cancer diagnosis may be as important as the specific type of malignancy observed.</p>
          <p><bold>Excess of multiple primary cancers.</bold> Individuals with LFS are also at increased risk of developing multiple primary tumors [<xref ref-type="bibr" rid="li-fraumeni.REF.gonzalez.2009b.1250">Gonzalez et al 2009b</xref>]. A retrospective study on 200 affected members of families with LFS found that 15% had developed a second cancer, 4% a third cancer, and 2% a total of four cancers. In this cohort, survivors of childhood cancers were found to have the highest risks for developing additional malignancies [<xref ref-type="bibr" rid="li-fraumeni.REF.hisada.1998.606">Hisada et al 1998</xref>]. The risk to individuals with LFS of developing a second cancer has been estimated at 57%, and the risk of a third malignancy 38%. The subsequent malignancies are not all clearly related to the treatment of the previous neoplasms.</p>
          <p><bold>Additional cancers.</bold> Although consensus holds that sarcomas, breast cancer, brain tumors, and ACCs constitute the core cancers of LFS, there is much less agreement about the non-core cancers which account for about 30% of malignancies in LFS.</p>
          <p>The following malignancies have been found to occur excessively in at least some families who have met criteria for LFS and/or have tested positive for germline <italic toggle="yes">TP53</italic> pathogenic variants [<xref ref-type="bibr" rid="li-fraumeni.REF.chompret.2000.1932">Chompret et al 2000</xref>, <xref ref-type="bibr" rid="li-fraumeni.REF.nichols.2001.83">Nichols et al 2001</xref>, <xref ref-type="bibr" rid="li-fraumeni.REF.olivier.2003.6643">Olivier et al 2003</xref>, <xref ref-type="bibr" rid="li-fraumeni.REF.varley.2003.313">Varley 2003</xref>, <xref ref-type="bibr" rid="li-fraumeni.REF.wong.2006.73">Wong et al 2006</xref>, <xref ref-type="bibr" rid="li-fraumeni.REF.gonzalez.2009b.1250">Gonzalez et al 2009b</xref>, <xref ref-type="bibr" rid="li-fraumeni.REF.ruijs.2010.421">Ruijs et al 2010</xref>]:</p>
          <list list-type="bullet">
            <list-item>
              <p><bold>Gastrointestinal cancers.</bold> Colorectal, esophageal, pancreatic, and stomach cancers have all been reported in families with LFS. One series reported a 2.8% incidence of colorectal cancer in people with <italic toggle="yes">TP53</italic> pathogenic variants with a mean age of diagnosis of 33 years [<xref ref-type="bibr" rid="li-fraumeni.REF.wong.2006.73">Wong et al 2006</xref>]. Another series reported that 22.6% of families with LFS had at least one relative with gastric cancer with a mean age of diagnosis of 43 years [<xref ref-type="bibr" rid="li-fraumeni.REF.masciari.2011.651">Masciari et al 2011</xref>].</p>
            </list-item>
            <list-item>
              <p><bold>Genitourinary cancers.</bold> Renal cell carcinomas have been reported in families with LFS. Endometrial, ovarian, prostate and gonadal germ cell tumors have all been reported in families with LFS.</p>
            </list-item>
            <list-item>
              <p><bold>Leukemias and lymphomas.</bold> Leukemias, especially the acute form, were initially considered a cardinal feature of LFS; however, more recent studies have determined that leukemias are not a major feature of LFS. Hodgkin and non-Hodgkin lymphomas have also been reported in families with LFS.</p>
            </list-item>
            <list-item>
              <p><bold>Lung cancers</bold> &#x02013; Increased risks for lung cancers have been reported in individuals with LFS, especially in those who use tobacco products [<xref ref-type="bibr" rid="li-fraumeni.REF.hwang.2003.238">Hwang et al 2003</xref>]. A rare form of lung cancer, termed bronchoalveolar cancer, is associated with LFS [<xref ref-type="bibr" rid="li-fraumeni.REF.tinat.2009.e108">Tinat et al 2009</xref>].</p>
            </list-item>
            <list-item>
              <p><bold>Neuroblastomas and other childhood cancers</bold> &#x02013; Children with germline<italic toggle="yes">TP53</italic> pathogenic variants may be at increased risk of developing neuroblastoma as well as other cancers of early childhood.</p>
            </list-item>
            <list-item>
              <p><bold>Skin cancers.</bold> Increased rates of melanoma and non-melanoma skin cancers have been reported in families with LFS.</p>
            </list-item>
            <list-item>
              <p><bold>Thyroid cancers.</bold> Non-medullary thyroid cancers have been reported in families with LFS.</p>
            </list-item>
          </list>
          <p><bold>Cancer risk.</bold> LFS is associated with high lifetime risks of cancer. The risk of cancer is estimated at 50% by age 30 years and 90% by age 60 years [<xref ref-type="bibr" rid="li-fraumeni.REF.lustbader.1992.344">Lustbader et al 1992</xref>].</p>
          <p>Age-specific cancer rates have also been assessed. One study, based on five families with LFS, estimated age-specific cancer risks (and standard errors) as 42% (0.14) at ages 0-16 years, 38% (0.14) at ages 17-45 years, and 63% (0.27) after age 45 years; overall lifetime cancer risk was calculated at 85%. In another series, 56% of cancers in families with LFS occurred prior to age 30 years and 100% were diagnosed by age 50 years [<xref ref-type="bibr" rid="li-fraumeni.REF.varley.1997.1">Varley et al 1997</xref>].</p>
          <p>The cancer risks in LFS demonstrate significant gender differences. For women with LFS, the lifetime risk of cancer is nearly 100% and for men with LFS, the lifetime risk of cancer is about 73% [<xref ref-type="bibr" rid="li-fraumeni.REF.chompret.2000.1932">Chompret et al 2000</xref>]. This gender difference in cancer risk is primarily the result of the high incidence of breast cancer among women with LFS [<xref ref-type="bibr" rid="li-fraumeni.REF.chompret.2000.1932">Chompret et al 2000</xref>, <xref ref-type="bibr" rid="li-fraumeni.REF.gonzalez.2009b.1250">Gonzalez et al 2009b</xref>]<italic toggle="yes">.</italic> However, in one series, the excessive cancer risk in females with LFS was observed at all stages of life, including childhood [<xref ref-type="bibr" rid="li-fraumeni.REF.hwang.2003.238">Hwang et al 2003</xref>, <xref ref-type="bibr" rid="li-fraumeni.REF.wu.2006.8287">Wu et al 2006</xref>].</p>
          <p>Ruijs and colleagues reported the following tumor-specific cancer risks based on observed versus expected cases in 24 families with LFS who had germline <italic toggle="yes">TP53</italic> pathogenic variants [<xref ref-type="bibr" rid="li-fraumeni.REF.ruijs.2010.421">Ruijs et al 2010</xref>]:</p>
          <table-wrap id="li-fraumeni.T.tumorspecific_cancer_risks" position="anchor" orientation="portrait">
            <label>Table 2. </label>
            <caption>
              <p>Tumor-Specific Cancer Risks in Families with LFS Who Have Germline <italic toggle="yes">TP53</italic> Pathogenic Variants</p>
            </caption>
            <table frame="hsides" rules="groups">
              <thead>
                <tr>
                  <th id="hd_h_li-fraumeni.T.tumorspecific_cancer_risks_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Tumor Type</th>
                  <th id="hd_h_li-fraumeni.T.tumorspecific_cancer_risks_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Relative Risk (95% CI)</th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td headers="hd_h_li-fraumeni.T.tumorspecific_cancer_risks_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Bone</td>
                  <td headers="hd_h_li-fraumeni.T.tumorspecific_cancer_risks_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">107 (49-203)</td>
                </tr>
                <tr>
                  <td headers="hd_h_li-fraumeni.T.tumorspecific_cancer_risks_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Connective Tissue</td>
                  <td headers="hd_h_li-fraumeni.T.tumorspecific_cancer_risks_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">61 (33-102)</td>
                </tr>
                <tr>
                  <td headers="hd_h_li-fraumeni.T.tumorspecific_cancer_risks_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Brain</td>
                  <td headers="hd_h_li-fraumeni.T.tumorspecific_cancer_risks_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">35 (19-60)</td>
                </tr>
                <tr>
                  <td headers="hd_h_li-fraumeni.T.tumorspecific_cancer_risks_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Pancreas</td>
                  <td headers="hd_h_li-fraumeni.T.tumorspecific_cancer_risks_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">7.3 (2-19)</td>
                </tr>
                <tr>
                  <td headers="hd_h_li-fraumeni.T.tumorspecific_cancer_risks_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Breast</td>
                  <td headers="hd_h_li-fraumeni.T.tumorspecific_cancer_risks_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">6.4 (4.3-9.3)</td>
                </tr>
                <tr>
                  <td headers="hd_h_li-fraumeni.T.tumorspecific_cancer_risks_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Colon</td>
                  <td headers="hd_h_li-fraumeni.T.tumorspecific_cancer_risks_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">2.8 (1-6)</td>
                </tr>
                <tr>
                  <td headers="hd_h_li-fraumeni.T.tumorspecific_cancer_risks_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Liver</td>
                  <td headers="hd_h_li-fraumeni.T.tumorspecific_cancer_risks_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">1.8 (2.1-64)</td>
                </tr>
              </tbody>
            </table>
            <table-wrap-foot>
              <fn>
                <p>Based on <xref ref-type="bibr" rid="li-fraumeni.REF.ruijs.2010.421">Ruijs et al [2010]</xref>; see p.425.</p>
              </fn>
            </table-wrap-foot>
          </table-wrap>
          <p>The relative risk for adrenocortical carcinoma could not be calculated in this series, because its occurrence in the general population is not known. Tumor-specific risk estimates have been difficult to establish in LFS, because of the rarity of the condition and the diverse spectrum of tumors.</p>
        </sec>
        <sec id="li-fraumeni.GenotypePhenotype_Correlatio">
          <title>Genotype-Phenotype Correlations</title>
          <p>The following anecdotal genotype-phenotype correlations have been reported in families with LFS with germline <italic toggle="yes">TP53</italic> pathogenic variants:</p>
          <list list-type="bullet">
            <list-item>
              <p>Pathogenic missense variants appear to be associated with earlier onset of cancer. In one series, the average age of tumor onset in heterozygotes for a <italic toggle="yes">TP53</italic> missense variant was eight years earlier (age 20.9 years vs 28.9 years) than for those with nonsense or other types of pathogenic variants. The authors suggest that in addition to inactivating <italic toggle="yes">TP53</italic>, a missense variant may confer a separate oncogenic effect [<xref ref-type="bibr" rid="li-fraumeni.REF.bougeard.2003.840">Bougeard et al 2003</xref>, <xref ref-type="bibr" rid="li-fraumeni.REF.palmero.2008.21">Palmero et al 2008</xref>].</p>
            </list-item>
            <list-item>
              <p>A deletion involving all or a part of <italic toggle="yes">TP53</italic> appears to confer phenotypes consistent with classic LFS [<xref ref-type="bibr" rid="li-fraumeni.REF.bougeard.2003.840">Bougeard et al 2003</xref>, <xref ref-type="bibr" rid="li-fraumeni.REF.shlien.2010.631">Shlien et al 2010</xref>]. This contrasts with individuals with deletions extending beyond <italic toggle="yes">TP53</italic>, who exhibit cognitive, developmental, neurologic, and other abnormalities and may be at a lower risk for tumor formation [<xref ref-type="bibr" rid="li-fraumeni.REF.shlien.2010.631">Shlien et al 2010</xref>].</p>
            </list-item>
            <list-item>
              <p>The risk for brain tumors appears to be increased if the <italic toggle="yes">TP53</italic> pathogenic variant lies in the DNA-binding loop that contacts the minor groove of DNA [<xref ref-type="bibr" rid="li-fraumeni.REF.olivier.2003.6643">Olivier et al 2003</xref>].</p>
            </list-item>
            <list-item>
              <p>The risk for ACC appears to be increased if the <italic toggle="yes">TP53</italic> pathogenic variant is located in the loops opposing the protein-DNA contact surface [<xref ref-type="bibr" rid="li-fraumeni.REF.olivier.2003.6643">Olivier et al 2003</xref>].</p>
            </list-item>
            <list-item>
              <p>The <italic toggle="yes">TP53</italic> pathogenic variant <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/protein/NP_000537.3">NP_000537.3</ext-link>:p.Arg337His has been found to be associated with increased risk for childhood adrenocortical carcinoma (ACC) in Brazilian studies. This pathogenic variant has also been identified in individuals with choroid plexus carcinoma, osteosarcoma, and breast cancer [<xref ref-type="bibr" rid="li-fraumeni.REF.assump__o.2008.357">Assump&#x000e7;&#x000e3;o et al 2008</xref>, <xref ref-type="bibr" rid="li-fraumeni.REF.custodio.2011.e18015">Custodio et al 2011</xref>, <xref ref-type="bibr" rid="li-fraumeni.REF.seidinger.2011.2228">Seidinger et al 2011</xref>, <xref ref-type="bibr" rid="li-fraumeni.REF.gomes.2012.3">Gomes et al 2012</xref>]. Evidence suggests that p.Arg337His may be a low-penetrance allele [<xref ref-type="bibr" rid="li-fraumeni.REF.achatz.2007.96">Achatz et al 2007</xref>, <xref ref-type="bibr" rid="li-fraumeni.REF.ribeiro.2007.353">Ribeiro et al 2007</xref>, <xref ref-type="bibr" rid="li-fraumeni.REF.palmero.2008.21">Palmero et al 2008</xref>]. However, it is important to note that the spectrum of cancers in families with the p.Arg337His pathogenic variant is beginning to resemble the pattern of cancer associated with other <italic toggle="yes">TP53</italic> pathogenic variants.</p>
            </list-item>
            <list-item>
              <p>Individuals with <italic toggle="yes">TP53</italic> pathogenic variants who also have certain genetic modifiers (e.g., a specific <italic toggle="yes">MDM2</italic> SNP309 allele or shortened telomere length) appear to develop cancer at earlier ages than individuals with a <italic toggle="yes">TP53</italic> pathogenic variant who do not have these genetic modifiers [<xref ref-type="bibr" rid="li-fraumeni.REF.bougeard.2003.840">Bougeard et al 2003</xref>, <xref ref-type="bibr" rid="li-fraumeni.REF.wu.2011.663">Wu et al 2011</xref>]. This information has not yet been used extensively in clinical counseling.</p>
            </list-item>
          </list>
          <p>There is some evidence that malignancies occur more frequently and at younger ages in families with LFS who have <italic toggle="yes">TP53</italic> pathogenic variants compared to families with LFS who do not have <italic toggle="yes">TP53</italic> pathogenic variants [<xref ref-type="bibr" rid="li-fraumeni.REF.olivier.2003.6643">Olivier et al 2003</xref>, <xref ref-type="bibr" rid="li-fraumeni.REF.wu.2006.8287">Wu et al 2006</xref>, <xref ref-type="bibr" rid="li-fraumeni.REF.gonzalez.2009b.1250">Gonzalez et al 2009b</xref>]<bold>.</bold></p>
        </sec>
        <sec id="li-fraumeni.Penetrance">
          <title>Penetrance</title>
          <p>LFS is a highly penetrant cancer syndrome. The risks for cancer in LFS are estimated to be 50% by age 30 years and 90% by age 60 years [<xref ref-type="bibr" rid="li-fraumeni.REF.lustbader.1992.344">Lustbader et al 1992</xref>]. However, men with LFS may have significantly lower lifetime risks of cancer than women [<xref ref-type="bibr" rid="li-fraumeni.REF.wu.2006.8287">Wu et al 2006</xref>] (see <xref ref-type="sec" rid="li-fraumeni.Clinical_Description">Clinical Description</xref>). These figures may still be somewhat biased, since individuals are typically offered <italic toggle="yes">TP53</italic> testing if they are diagnosed with cancer at unusually young ages.</p>
        </sec>
        <sec id="li-fraumeni.Anticipation">
          <title>Anticipation</title>
          <p>Families with LFS do appear to display genetic anticipation over successive generations.</p>
          <p>To date, two genetic modifiers have been identified:</p>
          <list list-type="bullet">
            <list-item>
              <p><bold><italic toggle="yes">MDM2</italic>.</bold>
<italic toggle="yes">MDM2</italic> is a direct negative regulator of <italic toggle="yes">TP53</italic>. The presence of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/nuccore/NM_002392.2">NM_002392.2</ext-link>:c.14+309G&#x0003e;T variant in the <italic toggle="yes">MDM2</italic> promoter region (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=rs2279744">rs2279744</ext-link>), termed SNP309 by the authors, has been associated with the development of tumors at significantly younger ages. This accelerated rate of tumor development has been observed in families with germline <italic toggle="yes">TP53</italic> pathogenic variants as well as individuals with sporadic tumors [<xref ref-type="bibr" rid="li-fraumeni.REF.bond.2004.591">Bond et al 2004</xref>, <xref ref-type="bibr" rid="li-fraumeni.REF.bougeard.2006.531">Bougeard et al 2006</xref>, <xref ref-type="bibr" rid="li-fraumeni.REF.ruijs.2007.110">Ruijs et al 2007</xref>]. A more recent study found that the <italic toggle="yes">MDM2</italic> SNP309 variant led to only a modest increased cancer risk in families with LFS [<xref ref-type="bibr" rid="li-fraumeni.REF.wu.2011.663">Wu et al 2011</xref>].</p>
            </list-item>
            <list-item>
              <p><bold>Telomere length.</bold> Shortened telomere length has been associated with accelerated tumor development in families with LFS [<xref ref-type="bibr" rid="li-fraumeni.REF.tabori.2007.1415">Tabori et al 2007</xref>, <xref ref-type="bibr" rid="li-fraumeni.REF.trkova.2007.694">Trkova et al 2007</xref>]. In one series, individuals with a <italic toggle="yes">TP53</italic> pathogenic variant who had childhood-onset malignancies had significantly shorter telomeres than their parents or unaffected siblings [<xref ref-type="bibr" rid="li-fraumeni.REF.bougeard.2003.840">Bougeard et al 2003</xref>].</p>
            </list-item>
          </list>
          <p>Another study looked at a possible generational or birth cohort effect in families with LFS, but concluded that this type of cohort effect did not adequately explain the rate of anticipation observed in families with LFS [<xref ref-type="bibr" rid="li-fraumeni.REF.brown.2005.489">Brown et al 2005</xref>].</p>
        </sec>
        <sec id="li-fraumeni.Prevalence">
          <title>Prevalence</title>
          <p>In the past, LFS was considered to be a rare hereditary cancer syndrome. However, recent data suggest that the frequency of germline <italic toggle="yes">TP53</italic> mutation may be as high as 1:5,000 to 1:20,000 [<xref ref-type="bibr" rid="li-fraumeni.REF.lalloo.2003.1101">Lalloo et al 2003</xref>, <xref ref-type="bibr" rid="li-fraumeni.REF.gonzalez.2009b.1250">Gonzalez et al 2009b</xref>]. As more families undergo <italic toggle="yes">TP53</italic> testing, the true prevalence of LFS may become clearer.</p>
        </sec>
      </sec>
      <sec id="li-fraumeni.Genetically_Related_Allelic">
        <title>Genetically Related (Allelic) Disorders</title>
        <p>Although acquired <italic toggle="yes">TP53</italic> pathogenic variants are observed in numerous tumors, no other inherited phenotypes are associated specifically with germline pathogenic variants involving <italic toggle="yes">TP53</italic>. Somatic <italic toggle="yes">TP53</italic> pathogenic variants are found in about 50% of all tumors, making it one of the genes most frequently altered in human cancers &#x02013; and most widely studied [<xref ref-type="bibr" rid="li-fraumeni.REF.meulmeester.2008.87">Meulmeester &#x00026; Jochemsen 2008</xref>, <xref ref-type="bibr" rid="li-fraumeni.REF.tomkova.2008.177">Tomkova et al 2008</xref>].</p>
        <p>A recent report describes a phenotypically distinct contiguous gene deletion syndrome caused by heterozygous germline deletions that include the chromosome 17p13.1 locus, in which there is loss of <italic toggle="yes">TP53</italic> as well as a number of adjacent genes. Affected individuals exhibit a common phenotype marked by developmental delay, hypotonia, and hand and foot abnormalities [<xref ref-type="bibr" rid="li-fraumeni.REF.shlien.2010.631">Shlien et al 2010</xref>]. It is not currently clear whether individuals with these contiguous gene deletions involving the 17p13.1 locus have cancer risks similar to or lower than those with <italic toggle="yes">TP53</italic> pathogenic variants.</p>
      </sec>
      <sec id="li-fraumeni.Differential_Diagnosis">
        <title>Differential Diagnosis</title>
        <p><related-object link-type="booklink" source-id="gene" document-id="brca1" document-type="chapter"><bold>Hereditary Breast-Ovarian Cancer syndrome</bold></related-object><bold>.</bold> Families who have a predominance of pre-menopausal breast cancer are more likely to have a pathogenic variant in <italic toggle="yes">BRCA1</italic> or <italic toggle="yes">BRCA2</italic> than in<italic toggle="yes">TP53</italic> [<xref ref-type="bibr" rid="li-fraumeni.REF.walsh.2006.1379">Walsh et al 2006</xref>]. Germline <italic toggle="yes">TP53</italic> pathogenic variants are thought to account for fewer than 1% of total breast cancer cases [<xref ref-type="bibr" rid="li-fraumeni.REF.sidransky.1992.2984">Sidransky et al 1992</xref>]. In one series, 4% of women who had breast cancer diagnosed before age 36 years and no other significant personal or family history had <italic toggle="yes">TP53</italic> pathogenic variants [<xref ref-type="bibr" rid="li-fraumeni.REF.tinat.2009.e108">Tinat et al 2009</xref>].</p>
        <p>Features of hereditary breast-ovarian cancer syndrome include cancers of the breast, ovary, pancreas, and prostate as well as melanoma. Childhood cancers are not increased among people with a single mutated <italic toggle="yes">BRCA1</italic> or <italic toggle="yes">BRCA2</italic> allele. The inheritance of two mutated <italic toggle="yes">BRCA2</italic> alleles causes <related-object link-type="booklink" source-id="gene" document-id="fa" document-type="chapter">Fanconi anemia</related-object> type D1.</p>
        <p>An individual who does not have an identifiable <italic toggle="yes">BRCA1</italic> or <italic toggle="yes">BRCA2</italic> pathogenic variant should be offered <italic toggle="yes">TP53</italic> testing if the individual has:</p>
        <list list-type="bullet">
          <list-item>
            <p>A personal and family history that includes at least some of the features of LFS [<xref ref-type="bibr" rid="li-fraumeni.REF.walsh.2006.1379">Walsh et al 2006</xref>];</p>
          </list-item>
          <list-item>
            <p>A personal history of breast cancer diagnosed before age 30 years [<xref ref-type="bibr" rid="li-fraumeni.REF.gonzalez.2009b.1250">Gonzalez et al 2009b</xref>].</p>
          </list-item>
        </list>
        <p><bold>Constitutional mismatch repair deficiency syndrome.</bold> Children who have developed leukemia, brain tumors, or early-onset gastrointestinal cancer may have constitutional mismatch repair deficiency (CMMR-D) syndrome. CMMR-D syndrome is caused by the inheritance of two mutated alleles of a mismatch repair (MMR) gene [<xref ref-type="bibr" rid="li-fraumeni.REF.tan.2008.254">Tan et al 2008</xref>]. The MMR genes include: <italic toggle="yes">MLH1</italic>, <italic toggle="yes">MSH2</italic>, <italic toggle="yes">MSH6</italic>, <italic toggle="yes">PMS1</italic>, and <italic toggle="yes">PMS2</italic>. Inheriting one mutated allele of an MMR gene causes <related-object link-type="booklink" source-id="gene" document-id="hnpcc" document-type="chapter">Hereditary nonpolyposis colorectal cancer</related-object> (HNPCC), also called Lynch syndrome. Individuals with Lynch syndrome whose partners have pathogenic variants in the same MMR gene are at 25% risk of having a child with CMMR-D syndrome.</p>
        <p>MMR genetic testing should be offered to children who have a personal history of caf&#x000e9; au lait spots and a malignancy or brain tumor plus a family history of colorectal cancer [<xref ref-type="bibr" rid="li-fraumeni.REF.tan.2008.254">Tan et al 2008</xref>].</p>
        <p>In families that have features of LFS and CMMR-D syndrome, it may be appropriate to offer genetic testing for both conditions.</p>
        <p><bold>Germline pathogenic variants in <italic toggle="yes">TP53</italic>-pathway genes.</bold> Several genes in the <italic toggle="yes">TP53</italic> pathway, including <italic toggle="yes">CHEK2</italic> and <italic toggle="yes">CDKN2A</italic>, have been analyzed as possible candidate genes for LFS. At this time, <italic toggle="yes">TP53</italic> is the only gene associated with LFS [<xref ref-type="bibr" rid="li-fraumeni.REF.malkin.2011.475">Malkin 2011</xref>]. Women with <italic toggle="yes">CHEK2</italic> pathogenic variants appear to be at increased risk for breast cancer. Men and women with <italic toggle="yes">CDKN2A</italic> pathogenic variants appear to be at increased risk for melanoma and pancreatic cancer.</p>
        <p>See <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/phenotypicSeries/PS151623">Li-Fraumeni Syndrome: OMIM Phenotypic Series</ext-link> to view genes associated with this phenotype in OMIM.</p>
      </sec>
      <sec id="li-fraumeni.Management">
        <title>Management</title>
        <sec id="li-fraumeni.Evaluations_Following_Initia">
          <title>Evaluations Following Initial Diagnosis</title>
          <p>Evaluation for cancer in an individual diagnosed with Li-Fraumeni syndrome (LFS) should be based on personal medical histories and to some extent, the specific pattern of cancer in the family. Testing can include comprehensive physical examination, neurologic examination, blood counts, imaging studies, endoscopies, and/or biopsies. Individuals diagnosed with or suspected of having LFS based on molecular or clinical criteria should seek a clinical genetics consultation to review the diagnosis and medical management recommendations.</p>
        </sec>
        <sec id="li-fraumeni.Treatment_of_Manifestations">
          <title>Treatment of Manifestations</title>
          <p>Women with LFS who develop breast cancer are encouraged to consider bilateral mastectomies (rather than lumpectomies) in order to reduce risks of developing a second primary breast tumor and avoid exposure to radiation therapy. However, most experts recommend that treatment efficacy be prioritized above concerns about late effects after careful analysis of risks and benefits. Aside from avoiding radiation therapy, LFS-related tumors are treated according to standard protocols.</p>
        </sec>
        <sec id="li-fraumeni.Prevention_of_Primary_Manife">
          <title>Prevention of Primary Manifestations</title>
          <p>Females with a germline <italic toggle="yes">TP53</italic> pathogenic variant have the option of prophylactic mastectomy to reduce the risk for breast cancer [<xref ref-type="bibr" rid="li-fraumeni.REF.thull.2004.13">Thull &#x00026; Vogel 2004</xref>]. Recent recommendations for colonoscopy may be considered surveillance as well as primary prevention of colorectal cancer. Counseling for avoidance of sun exposure, tobacco use, and exposure to other known or suspected carcinogens is encouraged.</p>
        </sec>
        <sec id="li-fraumeni.Prevention_of_Secondary_Comp">
          <title>Prevention of Secondary Complications</title>
          <p>Persons with a <italic toggle="yes">TP53</italic> pathogenic variant are cautioned to avoid radiation therapy whenever possible in order to limit the risk for secondary radiation-induced malignancies [<xref ref-type="bibr" rid="li-fraumeni.REF.evans.2006.289">Evans et al 2006</xref>]. However, when radiation is considered medically necessary to improve the chance of survival from a given malignancy, it may be used at the discretion of the treating physician and patient. The concern regarding radiation carcinogenesis is based on older data. There is interest in examining risks associated with more modern techniques, which may be less carcinogenic.</p>
          <p>Data on possible sensitivity to the carcinogenic effects of modern chemotherapy regimens are considerably more limited. In rare cases, individuals with germline <italic toggle="yes">TP53</italic> pathogenic variants have developed myelodysplastic syndrome and/or acute myeloid leukemia after treatment with radiation or chemotherapy for a prior tumor [<xref ref-type="bibr" rid="li-fraumeni.REF.hisada.2001.1979">Hisada et al 2001</xref>, <xref ref-type="bibr" rid="li-fraumeni.REF.kuribayashi.2005.490">Kuribayashi et al 2005</xref>, <xref ref-type="bibr" rid="li-fraumeni.REF.talwalkar.2010.1010">Talwalkar et al 2010</xref>].</p>
        </sec>
        <sec id="li-fraumeni.Surveillance">
          <title>Surveillance</title>
          <p>Clinicians and families need to be aware that currently no monitoring regimens have been definitively proven as beneficial for children or adults with germline <italic toggle="yes">TP53</italic> pathogenic variants. Nonetheless, this is an important area of ongoing investigation.</p>
          <p>The following is recommended:</p>
          <list list-type="bullet">
            <list-item>
              <p>Children and adults should undergo comprehensive annual physical examination including careful skin and neurologic examinations. Clinicians should be aware of the high risks for rare, early-onset cancers and also for second malignancies in cancer survivors [<xref ref-type="bibr" rid="li-fraumeni.REF51">NCCN 2012</xref>].</p>
            </list-item>
            <list-item>
              <p>Individuals should pay close attention to any lingering symptoms and illnesses, particularly headaches, bone pain, or abdominal discomfort. When present, the individual should see a physician promptly for evaluation [<xref ref-type="bibr" rid="li-fraumeni.REF.lindor.2008">Lindor et al 2008</xref>, <xref ref-type="bibr" rid="li-fraumeni.REF51">NCCN 2012</xref>].</p>
            </list-item>
            <list-item>
              <p>Women should undergo breast cancer monitoring, with annual breast MRI and twice-yearly clinical breast examination beginning at age 20-25 years. The use of mammograms has been controversial because of radiation exposure and limited sensitivity. When included, annual mammograms should alternate with breast MRI, with one modality every six months [<xref ref-type="bibr" rid="li-fraumeni.REF.lindor.2008">Lindor et al 2008</xref>, <xref ref-type="bibr" rid="li-fraumeni.REF51">NCCN 2012</xref>].</p>
            </list-item>
          </list>
          <p>The following is suggested:</p>
          <list list-type="bullet">
            <list-item>
              <p>Adults should consider routine screening for colorectal cancer with colonoscopy every two to three years beginning no later than age 25 years [<xref ref-type="bibr" rid="li-fraumeni.REF51">NCCN 2012</xref>].</p>
            </list-item>
            <list-item>
              <p>Individuals should consider organ-targeted surveillance based on the pattern of cancer observed in their family [<xref ref-type="bibr" rid="li-fraumeni.REF51">NCCN 2012</xref>].</p>
            </list-item>
          </list>
          <p>In adults with LFS, a pilot trial of screening [<sup>18</sup>F]-fluorodeoxyglucose positron emission tomography (FDG-PET)/CT scans detected tumors in three of 15 individuals. However, significant concerns were raised regarding the potential adverse consequences of the radiation exposure associated with PET/CT scans [<xref ref-type="bibr" rid="li-fraumeni.REF.masciari.2008.1315">Masciari et al 2008</xref>]. For this reason, attention has shifted to the utilization of whole-body MRI for adults with <italic toggle="yes">TP53</italic> pathogenic variants.</p>
          <p>Several groups have begun to utilize an intensive screening strategy including rapid whole-body MRI, brain MRI, abdominal ultrasound examination, and biochemical markers of adrenal cortical function. Preliminary data suggest that such a surveillance protocol may improve survival of individuals with LFS through presymptomatic detection of tumors [<xref ref-type="bibr" rid="li-fraumeni.REF.villani.2011.559">Villani et al 2011</xref>]. However, further prospective studies are needed to demonstrate the effectiveness of this protocol in adults and children with LFS.</p>
          <p>Individuals with LFS have been surveyed regarding their attitudes toward cancer surveillance, given its lack of known clinical benefit. Most individuals believed in the value of surveillance to detect tumors at an early stage and also reported psychological benefits (specifically, a sense of control and security) associated with participation in a regular surveillance program [<xref ref-type="bibr" rid="li-fraumeni.REF.lammens.2010b.647">Lammens et al 2010b</xref>].</p>
        </sec>
        <sec id="li-fraumeni.AgentsCircumstances_to_Avoid">
          <title>Agents/Circumstances to Avoid</title>
          <p>There is some evidence that <italic toggle="yes">TP53</italic> pathogenic variants confer an increased sensitivity to ionizing radiation [<xref ref-type="bibr" rid="li-fraumeni.REF.hisada.1998.606">Hisada et al 1998</xref>, <xref ref-type="bibr" rid="li-fraumeni.REF.varley.2003.313">Varley 2003</xref>, <xref ref-type="bibr" rid="li-fraumeni.REF.wang.2003.483">Wang et al 2003</xref>, <xref ref-type="bibr" rid="li-fraumeni.REF.cohen.2005.2391">Cohen et al 2005</xref>]. Thus, individuals with germline <italic toggle="yes">TP53</italic> pathogenic variants should avoid or minimize exposure to diagnostic and therapeutic radiation whenever possible [<xref ref-type="bibr" rid="li-fraumeni.REF.varley.2003.313">Varley 2003</xref>, <xref ref-type="bibr" rid="li-fraumeni.REF.evans.2006.289">Evans et al 2006</xref>]. Radiation-induced second malignancies have been reported among individuals with germline <italic toggle="yes">TP53</italic> pathogenic variants [<xref ref-type="bibr" rid="li-fraumeni.REF.hisada.1998.606">Hisada et al 1998</xref>, <xref ref-type="bibr" rid="li-fraumeni.REF.limacher.2001.238">Limacher et al 2001</xref>, <xref ref-type="bibr" rid="li-fraumeni.REF.cohen.2005.2391">Cohen et al 2005</xref>]. Detailed studies to more formally assess this risk are in development.</p>
          <p>Individuals with LFS are also encouraged to avoid or minimize exposures to known or suspected carcinogens, including sun exposure, tobacco use, occupational exposures, and excessive alcohol use, because the effects of carcinogenic exposures and germline <italic toggle="yes">TP53</italic> pathogenic variants may be cumulative. For example, individuals with a germline <italic toggle="yes">TP53</italic> pathogenic variant who smoke cigarettes have been shown to be at significantly increased risk of developing lung cancer than individuals with a germline <italic toggle="yes">TP53</italic> pathogenic variant who do not smoke [<xref ref-type="bibr" rid="li-fraumeni.REF.hwang.2003.238">Hwang et al 2003</xref>].</p>
        </sec>
        <sec id="li-fraumeni.Evaluation_of_Relatives_at_R">
          <title>Evaluation of Relatives at Risk</title>
          <p>Once a <italic toggle="yes">TP53</italic> pathogenic variant has been identified in a family, testing of at-risk relatives can identify those family members who also have the familial pathogenic variant and thus need increased surveillance and early intervention when a cancer is identified. However, families with LFS need to be cautioned that currently no definitive evidence demonstrates a benefit for increased surveillance or early intervention.</p>
          <p>See <xref ref-type="sec" rid="li-fraumeni.Related_Genetic_Counseling_I">Genetic Counseling</xref> for issues related to testing of at-risk relatives for genetic counseling purposes.</p>
        </sec>
        <sec id="li-fraumeni.Pregnancy_Management">
          <title>Pregnancy Management</title>
          <p>Women with LFS who are pregnant should bring any potential symptoms of cancer to the attention of their physicians. Women with LFS who are pregnant can continue to have clinical breast exams and/or breast imaging studies if indicated.</p>
          <p>There are no special recommendations for screening a fetus identified as having a germline<italic toggle="yes">TP53</italic> pathogenic variant. Once the infant is born, he or she can be evaluated for signs of cancer.</p>
        </sec>
        <sec id="li-fraumeni.Therapies_Under_Investigatio">
          <title>Therapies Under Investigation</title>
          <p>Search <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://clinicaltrials.gov/">ClinicalTrials.gov</ext-link> for access to information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.</p>
        </sec>
        <sec id="li-fraumeni.Other">
          <title>Other</title>
          <p>The Li-Fraumeni Exploration (LiFE) Research Consortium, formed in 2010, is a collaborative group of clinicians, scientists, genetic counselors, and psychologists who work with families with LFS and individuals from families with LFS [<xref ref-type="bibr" rid="li-fraumeni.REF.mai.2012.479">Mai et al 2012</xref>].</p>
        </sec>
      </sec>
      <sec id="li-fraumeni.Genetic_Counseling">
        <title>Genetic Counseling</title>
        <sec id="li-fraumeni.Mode_of_Inheritance">
          <title>Mode of Inheritance</title>
          <p>LFS is inherited in an autosomal dominant manner.</p>
        </sec>
        <sec id="li-fraumeni.Risk_to_Family_Members">
          <title>Risk to Family Members</title>
          <p>
            <bold>Parents of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>Most <italic toggle="yes">TP53</italic> pathogenic variants have been inherited from one of the proband&#x02019;s parents.</p>
            </list-item>
            <list-item>
              <p>If one parent has a significant personal and/or family history of cancer he/she should be tested first. Otherwise, both parents can be tested simultaneously.</p>
            </list-item>
            <list-item>
              <p>The frequency of <italic toggle="yes">de novo</italic> mutation is not well established, but is estimated to be between 7% and 20% [<xref ref-type="bibr" rid="li-fraumeni.REF.chompret.2000.1932">Chompret et al 2000</xref>, <xref ref-type="bibr" rid="li-fraumeni.REF.gonzalez.2009a.689">Gonzalez et al 2009a</xref>].</p>
            </list-item>
            <list-item>
              <p>Recommendations for the evaluation of parents of a child with LFS and no known family history of LFS include molecular genetic testing for the <italic toggle="yes">TP53</italic> pathogenic variant found in the proband, followed by appropriate medical surveillance if either parent is identified as having the pathogenic variant.</p>
            </list-item>
          </list>
          <p>Note: The family history may also appear to be negative because of failure to recognize the disorder in family members, early death of the parent before the onset of symptoms, or late onset of the disease in the affected parent.</p>
          <p>
            <bold>Sibs of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The risk to the proband&#x02019;s siblings depends on the genetic status of the proband&#x02019;s parents.</p>
            </list-item>
            <list-item>
              <p>If one of the proband&#x02019;s parents has the <italic toggle="yes">TP53</italic> pathogenic variant, each sib of the proband is at 50% risk of having the pathogenic variant and cancer risks associated with LFS.</p>
            </list-item>
            <list-item>
              <p>If neither parent has the <italic toggle="yes">TP53</italic> pathogenic variant found in the proband, the proband is assumed to have a <italic toggle="yes">de novo</italic> pathogenic variant and the risk to sibs appears to be low. However, the risk may be slightly greater than that of the general population because of the possibility of germline mosaicism. One case of somatic <italic toggle="yes">de novo</italic> mosaicism has been reported in a child who developed two LFS-related malignancies [<xref ref-type="bibr" rid="li-fraumeni.REF.prochazkova.2009.206">Prochazkova et al 2009</xref>].</p>
            </list-item>
            <list-item>
              <p>If the family meets clinical criteria for LFS but the <italic toggle="yes">TP53</italic> pathogenic variant cannot be identified in the proband, each sib is assumed to be at 50% risk of having LFS.</p>
            </list-item>
          </list>
          <p><bold>Offspring of a proband.</bold> Each child of a proband with a germline <italic toggle="yes">TP53</italic> pathogenic variant is at a 50% risk of inheriting the pathogenic variant and having the cancer risks associated with LFS.</p>
          <p><bold>Other family members of a proband.</bold> The risk to other family members depends on the genetic status of the proband's parents. If a parent is affected and/or has a <italic toggle="yes">TP53</italic> pathogenic variant, his or her family members are at risk.</p>
          <p>The specific risks of having the <italic toggle="yes">TP53</italic> pathogenic variant are as follows:</p>
          <list list-type="bullet">
            <list-item>
              <p>25% risk to second-degree relatives (grandparents, aunts, uncles, nieces, nephews, and grandchildren) (addressed above)</p>
            </list-item>
            <list-item>
              <p>12.5% risk to third-degree relatives (first-cousins, great-grandparents, great-aunts and great-uncles)</p>
            </list-item>
          </list>
        </sec>
        <sec id="li-fraumeni.Related_Genetic_Counseling_I">
          <title>Related Genetic Counseling Issues</title>
          <p>See Management, <xref ref-type="sec" rid="li-fraumeni.Evaluation_of_Relatives_at_R">Evaluation of Relatives at Risk</xref> for information on evaluating at-risk relatives for the purpose of early diagnosis and treatment.</p>
          <p><bold>Considerations in families with an apparent <italic toggle="yes">de novo</italic> pathogenic variant.</bold> When the parents of a proband with an autosomal dominant condition are genetically unaffected, it is possible that the child has a <italic toggle="yes">de novo</italic> pathogenic variant. Alternative explanations include variable expressivity (i.e., men with <italic toggle="yes">TP53</italic> pathogenic variants may not develop cancer) and germline mosaicism. Possible non-medical explanations including alternate paternity or maternity (e.g., with assisted reproduction) or undisclosed adoption could also be explored.</p>
          <p><bold>Genetic cancer risk assessment and counseling.</bold> Families with LFS can present with a wide variety of medical, psychological, and familial issues [<xref ref-type="bibr" rid="li-fraumeni.REF.chompret.2002.75">Chompret 2002</xref>, <xref ref-type="bibr" rid="li-fraumeni.REF.varley.2003.313">Varley 2003</xref>, <xref ref-type="bibr" rid="li-fraumeni.REF.peterson.2008.783">Peterson et al 2008</xref>, <xref ref-type="bibr" rid="li-fraumeni.REF.lammens.2010a.3008">Lammens et al 2010a</xref>].</p>
          <p>Uptake of predisposition testing for <italic toggle="yes">TP53</italic> pathogenic variants is reported to be about 40%-50%, indicating that many at-risk individuals elect not to be tested [<xref ref-type="bibr" rid="li-fraumeni.REF.patenaude.1996.241">Patenaude et al 1996</xref>, <xref ref-type="bibr" rid="li-fraumeni.REF.lammens.2010a.3008">Lammens et al 2010a</xref>]. Individuals undergoing genetic testing should receive pre- and post-test genetic counseling, including discussion of the accuracy and limitations of results, the medical and psychological implications of results to individuals and their families, the logistics of testing (including cost), and potential risks and benefits of testing.</p>
          <p>It is also important to determine motivations for the genetic counseling visit and the individual's level of understanding regarding the disorder.</p>
          <p>Perception of cancer risk varies widely among at-risk individuals and can influence testing decisions and the impact of the test results. These perceptions of risk can be influenced by a person's previous experiences with cancer and loss, ambivalence towards testing, and the number of relatives with cancer [<xref ref-type="bibr" rid="li-fraumeni.REF.peterson.2008.783">Peterson et al 2008</xref>].</p>
          <p>For a comprehensive description of the medical, psychosocial, and ethical ramifications of identifying at-risk individuals through cancer risk assessment with or without molecular genetic testing, see <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.cancer.gov/about-cancer/causes-prevention/genetics/risk-assessment-pdq">Cancer Genetics Risk Assessment and Counseling &#x02013; for health professionals</ext-link> (part of PDQ<sup>&#x000ae;</sup>, National Cancer Institute).</p>
          <p><bold>Cancer risk assessment modification based on age.</bold> Within families whose members have LFS, the prevalence of specific malignancies differs during childhood, adolescence, and adulthood [<xref ref-type="bibr" rid="li-fraumeni.REF.olivier.2003.6643">Olivier et al 2003</xref>]. The most common cancers observed in families with LFS per age group are:</p>
          <list list-type="bullet">
            <list-item>
              <p><bold>0-10 yrs.</bold> Soft tissue sarcomas, brain tumors, and ACC</p>
            </list-item>
            <list-item>
              <p><bold>11-20 yrs.</bold> Bone sarcomas</p>
            </list-item>
            <list-item>
              <p><bold>&#x0003e;20 yrs.</bold> Breast cancer and brain tumors</p>
            </list-item>
          </list>
          <p>At-risk individuals who remain cancer free into their 50s and 60s are at lower risk of having the familial <italic toggle="yes">TP53</italic> pathogenic variant. However, males who did not develop childhood cancers may present in their 50s with multiple primary tumors [<xref ref-type="bibr" rid="li-fraumeni.REF.wu.2006.8287">Wu et al 2006</xref>].</p>
          <p><bold>Testing of at-risk asymptomatic adults.</bold> In general, at-risk relatives should be offered genetic testing only for the specific disease-causing <italic toggle="yes">TP53</italic> variant previously identified in the family.</p>
          <p><bold>Molecular genetic testing of asymptomatic individuals younger than age 18 years.</bold> It is feasible to test at-risk children or adolescents for familial <italic toggle="yes">TP53</italic> pathogenic variants, but the potential risks, benefits, and limitations should be carefully considered beforehand. There are legitimate concerns about testing individuals younger than age 18 years for <italic toggle="yes">TP53</italic> pathogenic variants, including issues of informed consent among minors, the lack of proven surveillance or prevention strategies, and concerns about stigmatization and discrimination. Testing individuals younger than age 18 years for <italic toggle="yes">TP53</italic> pathogenic variants is best performed within a program which provides both pre-test and post-test information and support. In one series, four children underwent presymptomatic <italic toggle="yes">TP53</italic> mutation testing with pre- and post-test counseling before age 18 years with no negative consequences reported by the authors up to 12 years after genetic testing [<xref ref-type="bibr" rid="li-fraumeni.REF.evans.2010.65">Evans et al 2010</xref>]. Emerging data on screening protocols for children with LFS could alter recommendations about testing children for <italic toggle="yes">TP53</italic> pathogenic variants. See <xref ref-type="sec" rid="li-fraumeni.Management">Management</xref> for information on screening protocols.</p>
          <p>See also the National Society of Genetic Counselors <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://nsgc.org/p/bl/et/blogid=47&#x00026;blogaid=28">position statement</ext-link> on genetic testing of minors for adult-onset conditions and the American Academy of Pediatrics and American College of Medical Genetics and Genomics <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://pediatrics.aappublications.org/content/131/3/620.full.pdf">policy statement</ext-link>: ethical and policy issues in genetic testing and screening of children.</p>
          <p><bold>Collecting a cancer history.</bold> Collecting a cancer history for a family suspected of having LFS involves obtaining information on all childhood- and adult-onset malignancies among first-, second-, and third-degree relatives. This includes information about the age of onset and the type and site of each cancer diagnosis. Obtaining written confirmation of the cancer diagnoses is important; one study found that only 55% of non-breast cancer diagnoses in families with LFS were accurately recounted [<xref ref-type="bibr" rid="li-fraumeni.REF.schneider.2004.222">Schneider et al 2004</xref>].</p>
          <p>Details about relatives may be incorrect or incomplete for a variety of reasons. For example, cancer may be a topic that the family avoids, or a parent's death may have led to estrangement from relatives on that side of the family. In addition, collecting a cancer history for a family with possible LFS is often emotionally charged because of the number of cancer-related illnesses and deaths among close relatives.</p>
          <p>
            <bold>Family planning</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The optimal time for determination of genetic risk and discussion of the availability of prenatal testing is before pregnancy.</p>
            </list-item>
            <list-item>
              <p>It is appropriate to offer genetic counseling (including discussion of potential risks to offspring and reproductive options) to young adults who are affected or at risk.</p>
            </list-item>
          </list>
          <p><bold>DNA banking</bold> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of affected individuals.</p>
        </sec>
        <sec id="li-fraumeni.Prenatal_Testing">
          <title>Prenatal Testing</title>
          <p>Prenatal testing is possible for families with LFS [<xref ref-type="bibr" rid="li-fraumeni.REF.avigad.2004.541">Avigad et al 2004</xref>]. The familial <italic toggle="yes">TP53</italic> pathogenic variant must be identified before prenatal testing can be performed.</p>
          <p>Prenatal diagnosis for pregnancies at 50% risk for LFS is possible by analyzing DNA extracted from fetal cells obtained by amniocentesis usually performed at approximately 15 to 18 weeks' gestation or chorionic villus sampling (CVS) at approximately ten to 12 weeks' gestation.</p>
          <p>Note: Gestational age is expressed as menstrual weeks calculated either from the first day of the last normal menstrual period or by ultrasound measurements.</p>
          <p><bold>Preimplantation genetic diagnosis (PGD)</bold> may be an option for some individuals in whom a <italic toggle="yes">TP53</italic> pathogenic variant or a large deletion has been identified. Successful PGD has been reported for individuals with LFS [<xref ref-type="bibr" rid="li-fraumeni.REF.rechitsky.2002.148">Rechitsky et al 2002</xref>, <xref ref-type="bibr" rid="li-fraumeni.REF.simpson.2005.87">Simpson et al 2005</xref>].</p>
        </sec>
      </sec>
      <sec id="li-fraumeni.Resources">
        <title>Resources</title>
      </sec>
      <sec id="li-fraumeni.Molecular_Genetics">
        <title>Molecular Genetics</title>
        <sec id="li-fraumeni.Molecular_Genetic_Pathogenes">
          <title>Molecular Genetic Pathogenesis</title>
          <p><italic toggle="yes">TP53</italic> has been called "the guardian of the genome" and its protein plays major roles in both the regulation of cell growth and the maintenance of homeostasis.</p>
          <p>The loss of this important tumor suppressor gene decreases the likelihood that cells with genetic errors will be flagged for DNA repair or apoptosis. These DNA-damaged cells can go on to further proliferate, which can lead to a colony of abnormal cells and eventually a malignant tumor.</p>
          <p>The cellular tumor antigen p53 protein plays a major role in determining whether cells undergo arrest for purposes of DNA repair or programmed cell death (apoptosis). The cellular tumor antigen p53 protein acts as a checkpoint control following DNA damage, helping delay cell cycle progression until the damaged DNA can be repaired or proceed with programmed cell death. Upon recognizing damaged DNA, the normal cellular tumor antigen p53 protein either: (1) transcriptionally activates the downstream genes (e.g., <italic toggle="yes">CDKN1A, MDM2, GADD45A, Bax, IGFBP1</italic>, cyclin G1, cyclin G2) to repair the DNA; or (2) directly signals a "sensor" molecule that confirms the damage and initiates apoptosis. The ability to arrest the cell cycle, a key regulatory function, occurs with proper activation of the RB pathway, which is p53 mediated. The cellular tumor antigen p53 protein may also have a direct role in the DNA repair process [<xref ref-type="bibr" rid="li-fraumeni.REF.varley.1997.1">Varley et al 1997</xref>].</p>
          <p>Researchers are studying the effect of genetic modifiers on the risks for cancer in families known to have a <italic toggle="yes">TP53</italic> pathogenic variant. These genetic modifiers include shortened telomere length and a specific allele in <italic toggle="yes">MDM2</italic>. Research on these genetic modifiers may be helpful in refining the cancer risk in families with LFS and may ultimately be important risk factors in the development of sporadic cancers as well [<xref ref-type="bibr" rid="li-fraumeni.REF.lindor.2008">Lindor et al 2008</xref>].</p>
          <p><bold>Gene structure.</bold>
<italic toggle="yes">TP53</italic> is a tumor suppressor gene that is 20 kilobases (kb) in genomic length with 11 exons. Exon 1 is non-coding and contains two transcriptional start sites. Alternative splicing sites are found in intron 2 and between exons 9 and 10. A transcription initiation site is present in intron 4. Two promoters have been identified: a promoter that lies upstream from <italic toggle="yes">TP53</italic> and an internal promoter that lies in intron 1 [<xref ref-type="bibr" rid="li-fraumeni.REF.bourdon.2007.277">Bourdon 2007</xref>] (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/191170">OMIM</ext-link>). See <related-object source-id="gene" document-id="li-fraumeni" object-id="li-fraumeni.molgen.TA">Table A</related-object> for a detailed summary of gene and protein information.</p>
          <p><bold>Pathogenic allelic variants.</bold> Nearly 300 distinct germline <italic toggle="yes">TP53</italic> pathogenic variants have been described in the literature [<xref ref-type="bibr" rid="li-fraumeni.REF.lindor.2008">Lindor et al 2008</xref>]. See <related-object source-id="gene" document-id="li-fraumeni" object-id="li-fraumeni.molgen.TA">Table A</related-object>.</p>
          <p>The majority of reported <italic toggle="yes">TP53</italic> pathogenic variants are missense variants. Most <italic toggle="yes">TP53</italic> pathogenic variants have been reported within exons 5-8, which encode the core DNA-binding region of the gene. Deletions and splice site variants have also been reported, emphasizing the need to examine both coding and non-coding regions, especially in families that meet classic LFS criteria [<xref ref-type="bibr" rid="li-fraumeni.REF.bougeard.2003.840">Bougeard et al 2003</xref>, <xref ref-type="bibr" rid="li-fraumeni.REF.olivier.2003.6643">Olivier et al 2003</xref>]. For more information, see <related-object source-id="gene" document-id="li-fraumeni" object-id="li-fraumeni.molgen.TA">Table A</related-object>.</p>
          <p><bold>Normal gene product.</bold> The p53 protein is an important transcription factor. In response to cellular stress, the p53 protein becomes activated and regulates target genes to induce the following processes:</p>
          <list list-type="bullet">
            <list-item>
              <p>Cell cycle arrest</p>
            </list-item>
            <list-item>
              <p>Apoptosis</p>
            </list-item>
            <list-item>
              <p>Senescence</p>
            </list-item>
            <list-item>
              <p>DNA repair</p>
            </list-item>
            <list-item>
              <p>Changes in metabolism</p>
            </list-item>
          </list>
          <p>In unstressed cells, the p53 protein remains inactivated primarily as a result of the presence of the <italic toggle="yes">MDM2</italic> ligase (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/191170">OMIM</ext-link>).</p>
          <p>The p53 protein has five highly conserved domains that show little variation across species. Domain I is responsible for transactivation properties, while the remaining domains (II-V) make up the core DNA-binding domain [<xref ref-type="bibr" rid="li-fraumeni.REF.varley.1997.1">Varley et al 1997</xref>].</p>
          <p><bold>Abnormal gene product.</bold> Cells that lack activated p53 protein cannot activate the appropriate chain of events when DNA is damaged. Instead, these DNA-damaged cells will be allowed to survive and proliferate, which can lead to the development of a diverse number of malignancies. Mutant p53 protein can be involved in pathways triggering gene amplification due to the impaired DNA double-stranded break repair [<xref ref-type="bibr" rid="li-fraumeni.REF.sugawara.2011.535">Sugawara et al 2011</xref>]. In addition to causing the loss of p53 protein, <italic toggle="yes">TP53</italic> pathogenic missense variants may have an additional oncogenic effect [<xref ref-type="bibr" rid="li-fraumeni.REF.bougeard.2003.840">Bougeard et al 2003</xref>].</p>
          <p>Mutation of <italic toggle="yes">TP53</italic> may also cause increased oxidative stress to cells due to the loss of wild-type p53 function [<xref ref-type="bibr" rid="li-fraumeni.REF.yoshida.2012.444">Yoshida et al 2012</xref>]. The <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/protein/NP_000537.3">NP_000537.3</ext-link>:p.Arg337His pathogenic variant [<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/nuccore/NM_000546.5">NM_000546.5</ext-link>:c.1010G&#x0003e;A] has also been shown to confer abnormal oxidation at high physiologic pH levels [<xref ref-type="bibr" rid="li-fraumeni.REF.macedo.2012.e47010">Macedo et al 2012</xref>].</p>
        </sec>
      </sec>
      <sec id="li-fraumeni.References">
        <title>References</title>
        <sec id="li-fraumeni.Published_GuidelinesConsensu">
          <title>Published Guidelines/Consensus Statements</title>
          <ref-list id="li-fraumeni.Published_GuidelinesConsensu.reflist0">
            <ref id="li-fraumeni.REF1">
              <mixed-citation publication-type="webpage">American Society of Clinical Oncology. Policy statement update: genetic testing for cancer susceptibility. Available <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://jco.ascopubs.org/content/28/5/893.long">online</ext-link>; registration or institutional access required. 2010. Accessed 6-23-16.</mixed-citation>
            </ref>
            <ref id="li-fraumeni.REF2">
              <mixed-citation publication-type="webpage">Committee on Bioethics, Committee on Genetics, and American College of Medical Genetics and Genomics Social, Ethical, Legal Issues Committee. Ethical and policy issues in genetic testing and screening of children. Available <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://pediatrics.aappublications.org/content/131/3/620.full.pdf">online</ext-link>. 2013. Accessed 6-23-16.</mixed-citation>
            </ref>
            <ref id="li-fraumeni.REF3">
              <mixed-citation publication-type="webpage">National Society of Genetic Counselors. Position statement on genetic testing of minors for adult-onset conditions. Available <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://nsgc.org/p/bl/et/blogid=47&#x00026;blogaid=28">online</ext-link>. 2012. Accessed 6-23-16.</mixed-citation>
            </ref>
          </ref-list>
        </sec>
        <sec id="li-fraumeni.Literature_Cited">
          <title>Literature Cited</title>
          <ref-list id="li-fraumeni.Literature_Cited.reflist0">
            <ref id="li-fraumeni.REF.achatz.2007.96">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Achatz</surname>
                    <given-names>MI</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Olivier</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Le Calvez</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Martel-Planche</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lopes</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rossi</surname>
                    <given-names>BM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ashton-Prolla</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Giugliani</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Palmero</surname>
                    <given-names>EI</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vargas</surname>
                    <given-names>FR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Da Rocha</surname>
                    <given-names>JC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vettore</surname>
                    <given-names>AL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hainaut</surname>
                    <given-names>P</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>The TP53 mutation R337H, is associated with Li-Fraumeni and Li-Fraumeni-like syndrome in Brazilian families.</article-title>
                <source>Cancer Lett</source>
                <volume>245</volume>
                <fpage>96</fpage>
                <lpage>102</lpage>
                <pub-id pub-id-type="pmid">16494995</pub-id>
              </element-citation>
            </ref>
            <ref id="li-fraumeni.REF.assump__o.2008.357">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Assump&#x000e7;&#x000e3;o</surname>
                    <given-names>JG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Seidinger</surname>
                    <given-names>AL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mastellaro</surname>
                    <given-names>MJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ribeiro</surname>
                    <given-names>RC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zambetti</surname>
                    <given-names>GP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ganti</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Srivastava</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shurtleff</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pei</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zeferino</surname>
                    <given-names>LC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dufloth</surname>
                    <given-names>RM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brandalise</surname>
                    <given-names>SR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yunes</surname>
                    <given-names>JA</given-names>
                  </name>
                </person-group>
                <article-title>Association of the germline TP53 R337H mutation with breast cancer in southern Brazil.</article-title>
                <source>BMC Cancer.</source>
                <year>2008</year>
                <volume>8</volume>
                <fpage>357</fpage>
                <pub-id pub-id-type="pmid">19046423</pub-id>
              </element-citation>
            </ref>
            <ref id="li-fraumeni.REF.avigad.2004.541">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Avigad</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Peleg</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Barel</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Benyaminy</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ben-Baruch</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Taub</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shohat</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Goshen</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cohen</surname>
                    <given-names>IJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yaniv</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zalzov</surname>
                    <given-names>R</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Prenatal diagnosis in Li-Fraumeni syndrome</article-title>
                <source>J Pediatr Hematol Oncol</source>
                <volume>26</volume>
                <fpage>541</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">15342977</pub-id>
              </element-citation>
            </ref>
            <ref id="li-fraumeni.REF.birch.2001.4621">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Birch</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Alston</surname>
                    <given-names>RD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McNally</surname>
                    <given-names>RJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Evans</surname>
                    <given-names>DG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kelsey</surname>
                    <given-names>AM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Harris</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eden</surname>
                    <given-names>OB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Varley</surname>
                    <given-names>JM</given-names>
                  </name>
                </person-group>
                <year>2001</year>
                <article-title>Relative frequency and morphology of cancers in carriers of germline TP53 mutations.</article-title>
                <source>Oncogene</source>
                <volume>20</volume>
                <fpage>4621</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">11498785</pub-id>
              </element-citation>
            </ref>
            <ref id="li-fraumeni.REF.birch.1994.1298">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Birch</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hartley</surname>
                    <given-names>AL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tricker</surname>
                    <given-names>KJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Prosser</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Condie</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kelsey</surname>
                    <given-names>AM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Harries</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jones</surname>
                    <given-names>PH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Binchy</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Crowther</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Craft</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eden</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Evans</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Thompson</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mann</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Martin</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mitchell</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Santibanez-Koref</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>1994</year>
                <article-title>Prevalence and diversity of constitutional mutations in the p53 gene among 21 Li-Fraumeni families.</article-title>
                <source>Cancer Res</source>
                <volume>54</volume>
                <fpage>1298</fpage>
                <lpage>304</lpage>
                <pub-id pub-id-type="pmid">8118819</pub-id>
              </element-citation>
            </ref>
            <ref id="li-fraumeni.REF.bond.2004.591">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Bond</surname>
                    <given-names>GL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hu</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bone</surname>
                    <given-names>EE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Robins</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lutzker</surname>
                    <given-names>SG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Arva</surname>
                    <given-names>NC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bargonetti</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bartel</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Taubert</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wuerl</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Onel</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yip</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hwang</surname>
                    <given-names>SJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Strong</surname>
                    <given-names>LC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lozano</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Levine</surname>
                    <given-names>AJ</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans.</article-title>
                <source>Cell</source>
                <volume>119</volume>
                <fpage>591</fpage>
                <lpage>602</lpage>
                <pub-id pub-id-type="pmid">15550242</pub-id>
              </element-citation>
            </ref>
            <ref id="li-fraumeni.REF.bougeard.2006.531">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Bougeard</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Baert-Desurmont</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tournier</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vasseur</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Martin</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brugieres</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chompret</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bressac-de Paillerets</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stoppa-Lyonnet</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bonaiti-Pellie</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Frebourg</surname>
                    <given-names>T</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Impact of the MDM2 SNP309 and p53 Arg72Pro polymorphism on age of tumour onset in Li-Fraumeni syndrome.</article-title>
                <source>J Med Genet</source>
                <volume>43</volume>
                <fpage>531</fpage>
                <lpage>3</lpage>
                <pub-id pub-id-type="pmid">16258005</pub-id>
              </element-citation>
            </ref>
            <ref id="li-fraumeni.REF.bougeard.2003.840">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Bougeard</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brugieres</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chompret</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gesta</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Charbonnier</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Valent</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Martin</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Raux</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Feunteun</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bressac-de Paillerets</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Frebourg</surname>
                    <given-names>T</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>Screening for TP53 rearrangements in families with the Li-Fraumeni syndrome reveals a complete deletion of the TP53 gene.</article-title>
                <source>Oncogene</source>
                <volume>22</volume>
                <fpage>840</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">12584563</pub-id>
              </element-citation>
            </ref>
            <ref id="li-fraumeni.REF.bourdon.2007.277">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Bourdon</surname>
                    <given-names>JC</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>p53 and its isoforms in cancer.</article-title>
                <source>Br J Cancer</source>
                <volume>97</volume>
                <fpage>277</fpage>
                <lpage>82</lpage>
                <pub-id pub-id-type="pmid">17637683</pub-id>
              </element-citation>
            </ref>
            <ref id="li-fraumeni.REF.brown.2005.489">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Brown</surname>
                    <given-names>BW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Costello</surname>
                    <given-names>TJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hwang</surname>
                    <given-names>SJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Strong</surname>
                    <given-names>LC</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Generation or birth cohort effect on cancer risk in Li-Fraumeni syndrome.</article-title>
                <source>Hum Genet</source>
                <volume>118</volume>
                <fpage>489</fpage>
                <lpage>98</lpage>
                <pub-id pub-id-type="pmid">16284780</pub-id>
              </element-citation>
            </ref>
            <ref id="li-fraumeni.REF.chao.2007.1000">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Chao</surname>
                    <given-names>MM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Levine</surname>
                    <given-names>JE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ruiz</surname>
                    <given-names>RE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kohlmann</surname>
                    <given-names>WK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bower</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Petty</surname>
                    <given-names>EM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mody</surname>
                    <given-names>RJ</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>Malignant triton tumor in a patient with Li-Fraumeni syndrome and a novel TP53 mutation.</article-title>
                <source>Pediatr Blood Cancer</source>
                <volume>49</volume>
                <fpage>1000</fpage>
                <lpage>4</lpage>
                <pub-id pub-id-type="pmid">16333835</pub-id>
              </element-citation>
            </ref>
            <ref id="li-fraumeni.REF.chompret.2002.75">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Chompret</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>2002</year>
                <article-title>The Li-Fraumeni syndrome.</article-title>
                <source>Biochimie</source>
                <volume>84</volume>
                <fpage>75</fpage>
                <lpage>82</lpage>
                <pub-id pub-id-type="pmid">11900879</pub-id>
              </element-citation>
            </ref>
            <ref id="li-fraumeni.REF.chompret.2001.43">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Chompret</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Abel</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stoppa-Lyonnet</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brugieres</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pages</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Feunteun</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bonaiti-Pellie</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <year>2001</year>
                <article-title>Sensitivity and predictive value of criteria for p53 germline mutation screening.</article-title>
                <source>J Med Genet</source>
                <volume>38</volume>
                <fpage>43</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">11332399</pub-id>
              </element-citation>
            </ref>
            <ref id="li-fraumeni.REF.chompret.2000.1932">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Chompret</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brugieres</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ronsin</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gardes</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dessarps-Freichey</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Abel</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hua</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ligot</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dondon</surname>
                    <given-names>MG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bressac-de Paillerets</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Frebourg</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lemerle</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bonaiti-Pellie</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Feunteun</surname>
                    <given-names>J</given-names>
                  </name>
                </person-group>
                <year>2000</year>
                <article-title>P53 germline mutations in childhood cancers and cancer risk for carrier individuals.</article-title>
                <source>Br J Cancer</source>
                <volume>82</volume>
                <fpage>1932</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">10864200</pub-id>
              </element-citation>
            </ref>
            <ref id="li-fraumeni.REF.cohen.2005.2391">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Cohen</surname>
                    <given-names>RJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Curtis</surname>
                    <given-names>RE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Inskip</surname>
                    <given-names>PD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fraumeni</surname>
                    <given-names>JF</given-names>
                    <suffix>Jr</suffix>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>The risk of developing second cancers among survivors of childhood soft tissue sarcoma.</article-title>
                <source>Cancer</source>
                <volume>103</volume>
                <fpage>2391</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">15852362</pub-id>
              </element-citation>
            </ref>
            <ref id="li-fraumeni.REF.custodio.2011.e18015">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Custodio</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Taques</surname>
                    <given-names>GR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Figueiredo</surname>
                    <given-names>BC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gugelmin</surname>
                    <given-names>ES</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Oliveira Figueiredo</surname>
                    <given-names>MM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Watanabe</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pontarolo</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lalli</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Torres</surname>
                    <given-names>LF</given-names>
                  </name>
                </person-group>
                <year>2011</year>
                <article-title>Increased incidence of choroid plexus carcinoma due to the germline TP53 R337H mutation in southern Brazil.</article-title>
                <source>PLoS One</source>
                <volume>6</volume>
                <fpage>e18015</fpage>
                <pub-id pub-id-type="pmid">21445348</pub-id>
              </element-citation>
            </ref>
            <ref id="li-fraumeni.REF.evans.2006.289">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Evans</surname>
                    <given-names>DG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Birch</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ramsden</surname>
                    <given-names>RT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sharif</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Baser</surname>
                    <given-names>ME</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Malignant transformation and new primary tumours after therapeutic radiation for benign disease: substantial risks in certain tumour prone syndromes.</article-title>
                <source>J Med Genet</source>
                <volume>43</volume>
                <fpage>289</fpage>
                <lpage>94</lpage>
                <pub-id pub-id-type="pmid">16155191</pub-id>
              </element-citation>
            </ref>
            <ref id="li-fraumeni.REF.evans.2010.65">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Evans</surname>
                    <given-names>DG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lunt</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Clancy</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eeles</surname>
                    <given-names>R</given-names>
                  </name>
                </person-group>
                <year>2010</year>
                <article-title>Childhood predictive genetic testing for Li-Fraumeni syndrome.</article-title>
                <source>Fam Cancer</source>
                <volume>9</volume>
                <fpage>65</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">19404774</pub-id>
              </element-citation>
            </ref>
            <ref id="li-fraumeni.REF.gomes.2012.3">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Gomes</surname>
                    <given-names>MC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kotsopoulos</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Almeida</surname>
                    <given-names>GL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Costa</surname>
                    <given-names>MM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vieira</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Filho Fde</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pitombo</surname>
                    <given-names>MB</given-names>
                  </name>
                </person-group>
                <article-title>F Leal PR, Royer R, Zhang P, Narod SA. The R337H mutation in TP53 and breast cancer in Brazil.</article-title>
                <source>Hered Cancer Clin Pract.</source>
                <year>2012</year>
                <volume>10</volume>
                <fpage>3</fpage>
                <pub-id pub-id-type="pmid">22455664</pub-id>
              </element-citation>
            </ref>
            <ref id="li-fraumeni.REF.gonzalez.2009a.689">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Gonzalez</surname>
                    <given-names>KD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Buzin</surname>
                    <given-names>CH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Noltner</surname>
                    <given-names>KA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gu</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Li</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Malkin</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sommer</surname>
                    <given-names>SS</given-names>
                  </name>
                </person-group>
                <year>2009a</year>
                <article-title>High frequency of de novo mutations in Li-Fraumeni syndrome.</article-title>
                <source>J Med Genet</source>
                <volume>46</volume>
                <fpage>689</fpage>
                <lpage>93</lpage>
                <pub-id pub-id-type="pmid">19556618</pub-id>
              </element-citation>
            </ref>
            <ref id="li-fraumeni.REF.gonzalez.2009b.1250">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Gonzalez</surname>
                    <given-names>KD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Noltner</surname>
                    <given-names>KA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Buzin</surname>
                    <given-names>CH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gu</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wen-Fong</surname>
                    <given-names>CY</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nguyen</surname>
                    <given-names>VQ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Han</surname>
                    <given-names>JH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lowstuter</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Longmate</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sommer</surname>
                    <given-names>SS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Weitzel</surname>
                    <given-names>JN</given-names>
                  </name>
                </person-group>
                <year>2009b</year>
                <article-title>Beyond Li-Fraumeni syndrome: Clinical characteristics of families with p53 germline mutations.</article-title>
                <source>J Clin Oncol</source>
                <volume>27</volume>
                <fpage>1250</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">19204208</pub-id>
              </element-citation>
            </ref>
            <ref id="li-fraumeni.REF.gozali.2012.905">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Gozali</surname>
                    <given-names>AE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Britt</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shane</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gonzalez</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gilles</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McComb</surname>
                    <given-names>JG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Krieger</surname>
                    <given-names>MD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lavey</surname>
                    <given-names>RS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shlien</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Villablanca</surname>
                    <given-names>JG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Erdreich-Epstein</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dhall</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jubran</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tabori</surname>
                    <given-names>U</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Malkin</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Finlay</surname>
                    <given-names>JL</given-names>
                  </name>
                </person-group>
                <year>2012</year>
                <article-title>Choroid plexus tumors; management, outcome, and association with the Li-Fraumeni syndrome: the Children&#x02019;s Hospital Los Angeles (CHLA) experience, 1991-2010.</article-title>
                <source>Pediatr Blood Cancer</source>
                <volume>58</volume>
                <fpage>905</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">21990040</pub-id>
              </element-citation>
            </ref>
            <ref id="li-fraumeni.REF.herrmann.2012.e476">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Herrmann</surname>
                    <given-names>LJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Heinze</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fassnacht</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Willenberg</surname>
                    <given-names>HS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Quinkler</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Reisch</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zink</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Allolio</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hahner</surname>
                    <given-names>S</given-names>
                  </name>
                </person-group>
                <year>2012</year>
                <article-title>TP53 germline mutations in adult patients with adrenocortical carcinoma.</article-title>
                <source>J Clin Endocrinol Metab</source>
                <volume>97</volume>
                <fpage>E476</fpage>
                <lpage>85</lpage>
                <pub-id pub-id-type="pmid">22170717</pub-id>
              </element-citation>
            </ref>
            <ref id="li-fraumeni.REF.hisada.2001.1979">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Hisada</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Biggar</surname>
                    <given-names>RJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Greene</surname>
                    <given-names>MH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fraumeni</surname>
                    <given-names>JF</given-names>
                    <suffix>Jr</suffix>
                  </name>
                  <name name-style="western">
                    <surname>Travis</surname>
                    <given-names>LB</given-names>
                  </name>
                </person-group>
                <year>2001</year>
                <article-title>Solid tumors after chronic lymphocytic leukemia.</article-title>
                <source>Blood</source>
                <volume>98</volume>
                <fpage>1979</fpage>
                <lpage>81</lpage>
                <pub-id pub-id-type="pmid">11535538</pub-id>
              </element-citation>
            </ref>
            <ref id="li-fraumeni.REF.hisada.1998.606">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Hisada</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Garber</surname>
                    <given-names>JE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fung</surname>
                    <given-names>CY</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fraumeni</surname>
                    <given-names>JF</given-names>
                    <suffix>Jr</suffix>
                  </name>
                  <name name-style="western">
                    <surname>Li</surname>
                    <given-names>FP</given-names>
                  </name>
                </person-group>
                <year>1998</year>
                <article-title>Multiple primary cancers in families with Li-Fraumeni syndrome.</article-title>
                <source>J Natl Cancer Inst.</source>
                <volume>90</volume>
                <fpage>606</fpage>
                <lpage>11</lpage>
                <pub-id pub-id-type="pmid">9554443</pub-id>
              </element-citation>
            </ref>
            <ref id="li-fraumeni.REF.hwang.2003.238">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Hwang</surname>
                    <given-names>SJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cheng</surname>
                    <given-names>LS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lozano</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Amos</surname>
                    <given-names>CI</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gu</surname>
                    <given-names>X</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Strong</surname>
                    <given-names>LC</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>Lung cancer risk in germline p53 mutation carriers: association between an inherited cancer predisposition, cigarette smoking, and cancer risk.</article-title>
                <source>Hum Genet</source>
                <volume>113</volume>
                <fpage>238</fpage>
                <lpage>43</lpage>
                <pub-id pub-id-type="pmid">12802680</pub-id>
              </element-citation>
            </ref>
            <ref id="li-fraumeni.REF.krutilkova.2005.1597">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Krutilkova</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Trkova</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fleitz</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gregor</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Novotna</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Krepelova</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sumerauer</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kodet</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Siruckova</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Plevova</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bendova</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hedvicakova</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Foreman</surname>
                    <given-names>NK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sedlacek</surname>
                    <given-names>Z</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Identification of five new families strengthens the link between childhood choroid plexus carcinoma and germline TP53 mutations.</article-title>
                <source>Eur J Cancer</source>
                <volume>41</volume>
                <fpage>1597</fpage>
                <lpage>603</lpage>
                <pub-id pub-id-type="pmid">15925506</pub-id>
              </element-citation>
            </ref>
            <ref id="li-fraumeni.REF.kuribayashi.2005.490">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kuribayashi</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Matsunaga</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sakai</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wada</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tateno</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Murase</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fujimi</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Takimoto</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Terui</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kato</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sasaki</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Satoh</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Niitsu</surname>
                    <given-names>Y.</given-names>
                  </name>
                </person-group>
                <article-title>A patient with TP53 germline mutation developed Bowen's disease and myelodysplastic syndrome with myelofibrosis after chemotherapy against ovarian cancer.</article-title>
                <source>Intern Med.</source>
                <year>2005</year>
                <volume>44</volume>
                <fpage>490</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">15942101</pub-id>
              </element-citation>
            </ref>
            <ref id="li-fraumeni.REF.lalloo.2003.1101">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Lalloo</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Varley</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ellis</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moran</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>O'Dair</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pharoah</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Evans</surname>
                    <given-names>DG</given-names>
                  </name>
                  <collab>Early Onset Breast Cancer Study Group</collab>
                </person-group>
                <article-title>Prediction of pathogenic mutations in patients with early-onset breast cancer by family history.</article-title>
                <source>Lancet.</source>
                <year>2003</year>
                <volume>361</volume>
                <fpage>1101</fpage>
                <lpage>2</lpage>
                <pub-id pub-id-type="pmid">12672316</pub-id>
              </element-citation>
            </ref>
            <ref id="li-fraumeni.REF.lammens.2010a.3008">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Lammens</surname>
                    <given-names>CR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aaronson</surname>
                    <given-names>NK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wagner</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sijmons</surname>
                    <given-names>RH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ausems</surname>
                    <given-names>MG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vriends</surname>
                    <given-names>AH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ruijs</surname>
                    <given-names>MW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van Os</surname>
                    <given-names>TA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Spruijt</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>G&#x000f3;mez Garc&#x000ed;a</surname>
                    <given-names>EB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kluijt</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nagtegaal</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Verhoef</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bleiker</surname>
                    <given-names>EM</given-names>
                  </name>
                </person-group>
                <article-title>Genetic testing in Li-Fraumeni syndrome: uptake and psychosocial consequences.</article-title>
                <source>J Clin Oncol.</source>
                <year>2010a</year>
                <volume>28</volume>
                <fpage>3008</fpage>
                <lpage>14</lpage>
                <pub-id pub-id-type="pmid">20479422</pub-id>
              </element-citation>
            </ref>
            <ref id="li-fraumeni.REF.lammens.2010b.647">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Lammens</surname>
                    <given-names>CR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bleiker</surname>
                    <given-names>EM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aaronson</surname>
                    <given-names>NK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wagner</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sijmons</surname>
                    <given-names>RH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ausems</surname>
                    <given-names>MG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vriends</surname>
                    <given-names>AH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ruijs</surname>
                    <given-names>MW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van Os</surname>
                    <given-names>TA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Spruijt</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>G&#x000f3;mez Garc&#x000ed;a</surname>
                    <given-names>EB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cats</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nagtegaal</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Verhoef</surname>
                    <given-names>S</given-names>
                  </name>
                </person-group>
                <article-title>Regular surveillance for Li-Fraumeni Syndrome: advice, adherence and perceived benefits.</article-title>
                <source>Fam Cancer.</source>
                <year>2010b</year>
                <volume>9</volume>
                <fpage>647</fpage>
                <lpage>54</lpage>
                <pub-id pub-id-type="pmid">20658357</pub-id>
              </element-citation>
            </ref>
            <ref id="li-fraumeni.REF.lee.2012.r66">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Lee</surname>
                    <given-names>DS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yoon</surname>
                    <given-names>SY</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Looi</surname>
                    <given-names>LM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kang</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kang</surname>
                    <given-names>IN</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sivanandan</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ariffin</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Thong</surname>
                    <given-names>MK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chin</surname>
                    <given-names>KF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mohd Taib</surname>
                    <given-names>NA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yip</surname>
                    <given-names>CH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Teo</surname>
                    <given-names>SH</given-names>
                  </name>
                </person-group>
                <year>2012</year>
                <article-title>Comparable frequency of BRCA1, BRCA2 and TP53 germline mutations in a multi-ethnic Asian cohort suggests TP53 screening should be offered together with BRCA1/2 screening to early-onset breast cancer patients.</article-title>
                <source>Breast Cancer Res</source>
                <volume>14</volume>
                <fpage>R66</fpage>
                <pub-id pub-id-type="pmid">22507745</pub-id>
              </element-citation>
            </ref>
            <ref id="li-fraumeni.REF.li.1988.5358">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Li</surname>
                    <given-names>FP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fraumeni</surname>
                    <given-names>JF</given-names>
                    <suffix>Jr</suffix>
                  </name>
                  <name name-style="western">
                    <surname>Mulvihill</surname>
                    <given-names>JJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Blattner</surname>
                    <given-names>WA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dreyfus</surname>
                    <given-names>MG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tucker</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Miller</surname>
                    <given-names>RW</given-names>
                  </name>
                </person-group>
                <year>1988</year>
                <article-title>A cancer family syndrome in twenty-four kindreds.</article-title>
                <source>Cancer Res</source>
                <volume>48</volume>
                <fpage>5358</fpage>
                <lpage>62</lpage>
                <pub-id pub-id-type="pmid">3409256</pub-id>
              </element-citation>
            </ref>
            <ref id="li-fraumeni.REF.lib_.2005.477">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Lib&#x000e9;</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bertherat</surname>
                    <given-names>J</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Molecular genetics of adrenocortical tumours, from familial to sporadic diseases.</article-title>
                <source>Eur J Endocrinol</source>
                <volume>153</volume>
                <fpage>477</fpage>
                <lpage>87</lpage>
                <pub-id pub-id-type="pmid">16189167</pub-id>
              </element-citation>
            </ref>
            <ref id="li-fraumeni.REF.limacher.2001.238">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Limacher</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Frebourg</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Natarajan-Ame</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bergerat</surname>
                    <given-names>JP</given-names>
                  </name>
                </person-group>
                <year>2001</year>
                <article-title>Two metachronous tumors in the radiotherapy fields of a patient with Li-Fraumeni syndrome.</article-title>
                <source>Int J Cancer</source>
                <volume>96</volume>
                <fpage>238</fpage>
                <lpage>42</lpage>
                <pub-id pub-id-type="pmid">11474498</pub-id>
              </element-citation>
            </ref>
            <ref id="li-fraumeni.REF.lindor.2008">
              <mixed-citation publication-type="book">Lindor NM, McMaster ML, Lindor CJ, Greene MH, National Cancer Institute, Division of Cancer Prevention, Community Oncology and Prevention Trials Research Group (2008): Li-Fraumeni syndrome. In Concise Handbook of Familial Cancer Susceptibility Syndromes &#x02013; Second Edition. J Natl Cancer Inst Monogr 38:80-5.</mixed-citation>
            </ref>
            <ref id="li-fraumeni.REF.lustbader.1992.344">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Lustbader</surname>
                    <given-names>ED</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Williams</surname>
                    <given-names>WR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bondy</surname>
                    <given-names>ML</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Strom</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Strong</surname>
                    <given-names>LC</given-names>
                  </name>
                </person-group>
                <year>1992</year>
                <article-title>Segregation analysis of cancer in families of childhood soft tissue sarcoma patients.</article-title>
                <source>Am J Hum Genet</source>
                <volume>51</volume>
                <fpage>344</fpage>
                <lpage>56</lpage>
                <pub-id pub-id-type="pmid">1642235</pub-id>
              </element-citation>
            </ref>
            <ref id="li-fraumeni.REF.macedo.2012.e47010">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Macedo</surname>
                    <given-names>GS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lisb&#x000f4;a da Motta</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Giacomazzi</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Netto</surname>
                    <given-names>CB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Manfredini</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vanzin</surname>
                    <given-names>CS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vargas</surname>
                    <given-names>CR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hainaut</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Klamt</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ashton-Prolla</surname>
                    <given-names>P</given-names>
                  </name>
                </person-group>
                <article-title>Increased oxidative damage in carriers of the germline TP53 p.R337H mutation.</article-title>
                <source>PLoS One.</source>
                <year>2012</year>
                <volume>7</volume>
                <fpage>e47010</fpage>
                <pub-id pub-id-type="pmid">23056559</pub-id>
              </element-citation>
            </ref>
            <ref id="li-fraumeni.REF.mai.2012.479">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Mai</surname>
                    <given-names>PL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Malkin</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Garber</surname>
                    <given-names>JE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schiffman</surname>
                    <given-names>JD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Weitzel</surname>
                    <given-names>JN</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Strong</surname>
                    <given-names>LC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wyss</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Locke</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Means</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Achatz</surname>
                    <given-names>MI</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hainaut</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Frebourg</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Evans</surname>
                    <given-names>DG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bleiker</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Patenaude</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schneider</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wilfod</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Peters</surname>
                    <given-names>JA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hwang</surname>
                    <given-names>PM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ford</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tabori</surname>
                    <given-names>U</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ognjanovic</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dennis</surname>
                    <given-names>PA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wentzensen</surname>
                    <given-names>IM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Greene</surname>
                    <given-names>MH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fraumeni</surname>
                    <given-names>JF</given-names>
                    <suffix>Jr</suffix>
                  </name>
                  <name name-style="western">
                    <surname>Savage</surname>
                    <given-names>SA</given-names>
                  </name>
                </person-group>
                <year>2012</year>
                <article-title>Li-Fraumeni syndrome: report of a clinical research workshop and creation of a research consortium.</article-title>
                <source>Cancer Genet</source>
                <volume>205</volume>
                <fpage>479</fpage>
                <lpage>87</lpage>
                <pub-id pub-id-type="pmid">22939227</pub-id>
              </element-citation>
            </ref>
            <ref id="li-fraumeni.REF.malkin.2011.475">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Malkin</surname>
                    <given-names>D</given-names>
                  </name>
                </person-group>
                <year>2011</year>
                <article-title>Li-Fraumeni syndrome.</article-title>
                <source>Genes Cancer</source>
                <volume>2</volume>
                <fpage>475</fpage>
                <lpage>84</lpage>
                <pub-id pub-id-type="pmid">21779515</pub-id>
              </element-citation>
            </ref>
            <ref id="li-fraumeni.REF.masciari.2011.651">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Masciari</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dewanwala</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stoffel</surname>
                    <given-names>EM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lauwers</surname>
                    <given-names>GY</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zheng</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Achatz</surname>
                    <given-names>MI</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Reigert-Johnson</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Foretova</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Silva</surname>
                    <given-names>EM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Digianni</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Verselis</surname>
                    <given-names>SJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schneider</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Li</surname>
                    <given-names>FP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fraumeni</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Garber</surname>
                    <given-names>JE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Syngal</surname>
                    <given-names>S</given-names>
                  </name>
                </person-group>
                <year>2011</year>
                <article-title>Gastric cancer in individuals with Li-Fraumeni syndrome.</article-title>
                <source>Genet Med</source>
                <volume>13</volume>
                <fpage>651</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">21552135</pub-id>
              </element-citation>
            </ref>
            <ref id="li-fraumeni.REF.masciari.2012.1125">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Masciari</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dillon</surname>
                    <given-names>DA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rath</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Robson</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Weitzel</surname>
                    <given-names>JN</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Balmana</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gruber</surname>
                    <given-names>SB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ford</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Euhus</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lebensohn</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Telli</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pochebit</surname>
                    <given-names>SM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lypas</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Garber</surname>
                    <given-names>JE</given-names>
                  </name>
                </person-group>
                <year>2012</year>
                <article-title>Breast cancer phenotype in women with TP53 germline mutations: A Li-Fraumeni syndrome consortium effort.</article-title>
                <source>Breast Cancer Res Treat</source>
                <volume>133</volume>
                <fpage>1125</fpage>
                <lpage>30</lpage>
                <pub-id pub-id-type="pmid">22392042</pub-id>
              </element-citation>
            </ref>
            <ref id="li-fraumeni.REF.masciari.2008.1315">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Masciari</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Van den Abbeele</surname>
                    <given-names>AD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Diller</surname>
                    <given-names>LR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rastarhuyeva</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yap</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schneier</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Digianni</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Li</surname>
                    <given-names>FP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fraumeni</surname>
                    <given-names>JF</given-names>
                    <suffix>Jr</suffix>
                  </name>
                  <name name-style="western">
                    <surname>Syngal</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Garber</surname>
                    <given-names>JE</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>F18-Fluorodeoxyglucose-Positron Emission Tomography/Computed tomography screening in Li-Fraumeni syndrome.</article-title>
                <source>JAMA</source>
                <volume>299</volume>
                <fpage>1315</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">18349092</pub-id>
              </element-citation>
            </ref>
            <ref id="li-fraumeni.REF.mccuaig.2012.607">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>McCuaig</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Armel</surname>
                    <given-names>SR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Novokmet</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ginsburg</surname>
                    <given-names>OM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Demsky</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Narod</surname>
                    <given-names>SA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Malkin</surname>
                    <given-names>D</given-names>
                  </name>
                </person-group>
                <year>2012</year>
                <article-title>Routine TP53 testing for breast cancer under age 30: ready for prime time?</article-title>
                <source>Fam Cancer</source>
                <volume>11</volume>
                <fpage>607</fpage>
                <lpage>13</lpage>
                <pub-id pub-id-type="pmid">22851211</pub-id>
              </element-citation>
            </ref>
            <ref id="li-fraumeni.REF.melhembertrandt.2012.908">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Melhem-Bertrandt</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bojadzieva</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ready</surname>
                    <given-names>KJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Obeid</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Liu</surname>
                    <given-names>DD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gutierrez-Barrera</surname>
                    <given-names>AM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Litton</surname>
                    <given-names>JK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Olopade</surname>
                    <given-names>OI</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hortobagyi</surname>
                    <given-names>GN</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Strong</surname>
                    <given-names>LC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Arun</surname>
                    <given-names>BK</given-names>
                  </name>
                </person-group>
                <year>2012</year>
                <article-title>Early onset HER2-positive breast cancer is associated with germline TP53 mutations.</article-title>
                <source>Cancer</source>
                <volume>118</volume>
                <fpage>908</fpage>
                <lpage>13</lpage>
                <pub-id pub-id-type="pmid">21761402</pub-id>
              </element-citation>
            </ref>
            <ref id="li-fraumeni.REF.meulmeester.2008.87">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Meulmeester</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jochemsen</surname>
                    <given-names>AG</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>p53: a guide to apoptosis.</article-title>
                <source>Curr Cancer Drug Targets</source>
                <volume>8</volume>
                <fpage>87</fpage>
                <lpage>97</lpage>
                <pub-id pub-id-type="pmid">18336191</pub-id>
              </element-citation>
            </ref>
            <ref id="li-fraumeni.REF.mouchawar.2010.4795">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Mouchawar</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Korch</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Byers</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pitts</surname>
                    <given-names>TM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Li</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McCredie</surname>
                    <given-names>MR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Giles</surname>
                    <given-names>GG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hopper</surname>
                    <given-names>JL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Southey</surname>
                    <given-names>MC</given-names>
                  </name>
                </person-group>
                <year>2010</year>
                <article-title>Population-based estimate of the contribution of TP53 mutations to subgroups of early-onset breast cancer: Australian Breast Cancer Family Study.</article-title>
                <source>Cancer Res</source>
                <volume>70</volume>
                <fpage>4795</fpage>
                <lpage>800</lpage>
                <pub-id pub-id-type="pmid">20501846</pub-id>
              </element-citation>
            </ref>
            <ref id="li-fraumeni.REF51">
              <mixed-citation publication-type="webpage">NCCN. The National Comprehensive Cancer Network Clinical Practice Guidelines&#x000ae; in Oncology: Li-Fraumeni syndrome (Version 1.2012). &#x000a9; 2009 National Comprehensive Cancer Network, Inc. Available at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.nccn.org/clinical.asp">online</ext-link> (registration required). 2012. Accessed 6-23-16.</mixed-citation>
            </ref>
            <ref id="li-fraumeni.REF.nichols.2001.83">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Nichols</surname>
                    <given-names>KE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Malkin</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Garber</surname>
                    <given-names>JE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fraumeni</surname>
                    <given-names>JF</given-names>
                    <suffix>Jr</suffix>
                  </name>
                  <name name-style="western">
                    <surname>Li</surname>
                    <given-names>FP</given-names>
                  </name>
                </person-group>
                <year>2001</year>
                <article-title>Germ-line p53 mutations predispose to a wide spectrum of early-onset cancers.</article-title>
                <source>Cancer Epidemiol Biomarkers Prev</source>
                <volume>10</volume>
                <fpage>83</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">11219776</pub-id>
              </element-citation>
            </ref>
            <ref id="li-fraumeni.REF.ognjanovic.2012.1387">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ognjanovic</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Olivier</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bergemann</surname>
                    <given-names>TL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hainaut</surname>
                    <given-names>P</given-names>
                  </name>
                </person-group>
                <year>2012</year>
                <article-title>Sarcomas in TP53 germline mutation carriers: A review of the IARC TP53 database.</article-title>
                <source>Cancer</source>
                <volume>118</volume>
                <fpage>1387</fpage>
                <lpage>96</lpage>
                <pub-id pub-id-type="pmid">21837677</pub-id>
              </element-citation>
            </ref>
            <ref id="li-fraumeni.REF.olivier.2003.6643">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Olivier</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Goldgar</surname>
                    <given-names>DE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sodha</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ohgaki</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kleihues</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hainaut</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eeles</surname>
                    <given-names>RA</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype.</article-title>
                <source>Cancer Res</source>
                <volume>63</volume>
                <fpage>6643</fpage>
                <lpage>50</lpage>
                <pub-id pub-id-type="pmid">14583457</pub-id>
              </element-citation>
            </ref>
            <ref id="li-fraumeni.REF.palmero.2008.21">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Palmero</surname>
                    <given-names>EI</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schuler-Faccini</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Caleffi</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Achatz</surname>
                    <given-names>MI</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Olivier</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Martel-Planche</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Marcel</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aguiar</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Giacomazzi</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ewald</surname>
                    <given-names>IP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Giugliani</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hainaut</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ashton-Prolia</surname>
                    <given-names>P</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>Detection of R337H, a germline TP53 mutation predisposing to multiple cancers, in asymptomatic women participating in a breast cancer screening program in southern Brazil.</article-title>
                <source>Cancer Lett</source>
                <volume>261</volume>
                <fpage>21</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">18248785</pub-id>
              </element-citation>
            </ref>
            <ref id="li-fraumeni.REF.patenaude.1996.241">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Patenaude</surname>
                    <given-names>AF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schneider</surname>
                    <given-names>KA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kieffer</surname>
                    <given-names>SA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Calzone</surname>
                    <given-names>KA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stopfer</surname>
                    <given-names>JE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Basili</surname>
                    <given-names>LA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Weber</surname>
                    <given-names>BL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Garber</surname>
                    <given-names>JE</given-names>
                  </name>
                </person-group>
                <year>1996</year>
                <article-title>Acceptance of invitations for TP53 and BRCA1 predisposition testing: factors influencing potential utilization of cancer genetic testing.</article-title>
                <source>Psycho-Oncology</source>
                <volume>5</volume>
                <fpage>241</fpage>
                <lpage>50</lpage>
              </element-citation>
            </ref>
            <ref id="li-fraumeni.REF.peterson.2008.783">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Peterson</surname>
                    <given-names>SK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pentz</surname>
                    <given-names>RD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Marani</surname>
                    <given-names>SK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ward</surname>
                    <given-names>PA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Blanco</surname>
                    <given-names>AM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>LaRue</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vogel</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Solomon</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Strong</surname>
                    <given-names>LC</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>Psychological functioning in persons considering genetic counseling and testing for Li-Fraumeni syndrome.</article-title>
                <source>Psycho-Oncology</source>
                <volume>17</volume>
                <fpage>783</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">18688785</pub-id>
              </element-citation>
            </ref>
            <ref id="li-fraumeni.REF.prochazkova.2009.206">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Prochazkova</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pavlikova</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Minarik</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sumerauer</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kodet</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sedlacek</surname>
                    <given-names>Z</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>Somatic TP53 mutation mosaicism in a patient with Li-Fraumeni syndrome.</article-title>
                <source>Am J Med Genet A</source>
                <volume>149A</volume>
                <fpage>206</fpage>
                <lpage>11</lpage>
                <pub-id pub-id-type="pmid">19012332</pub-id>
              </element-citation>
            </ref>
            <ref id="li-fraumeni.REF.raymond.2013.e119">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Raymond</surname>
                    <given-names>VM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Else</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Everett</surname>
                    <given-names>JN</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Long</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gruber</surname>
                    <given-names>SB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hammer</surname>
                    <given-names>GD</given-names>
                  </name>
                </person-group>
                <year>2013</year>
                <article-title>Prevalence of germline TP53 mutations in a prospective series of unselected patients with adrenocortical carcinoma.</article-title>
                <source>J Clin Endocrinol Metab.</source>
                <volume>98</volume>
                <fpage>E119</fpage>
                <lpage>25</lpage>
                <pub-id pub-id-type="pmid">23175693</pub-id>
              </element-citation>
            </ref>
            <ref id="li-fraumeni.REF.rechitsky.2002.148">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Rechitsky</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Verlinsky</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chistokhina</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sharapova</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ozen</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Masciangelo</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kuliev</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Verlinsky</surname>
                    <given-names>Y</given-names>
                  </name>
                </person-group>
                <year>2002</year>
                <article-title>Preimplantation genetic diagnosis for cancer predisposition.</article-title>
                <source>Reprod Biomed Online</source>
                <volume>5</volume>
                <fpage>148</fpage>
                <lpage>55</lpage>
                <pub-id pub-id-type="pmid">12419039</pub-id>
              </element-citation>
            </ref>
            <ref id="li-fraumeni.REF.ribeiro.2007.353">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ribeiro</surname>
                    <given-names>RC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rodriguez-Galindo</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Figueiredo</surname>
                    <given-names>BC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mastellaro</surname>
                    <given-names>MJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>West</surname>
                    <given-names>AN</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kriwacki</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zambetti</surname>
                    <given-names>GP</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>Germline TP53 R337H mutation is not sufficient to establish Li-Fraumeni or Li-Fraumeni like syndrome.</article-title>
                <source>Cancer Lett</source>
                <volume>247</volume>
                <fpage>353</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">16750598</pub-id>
              </element-citation>
            </ref>
            <ref id="li-fraumeni.REF.ruijs.2007.110">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ruijs</surname>
                    <given-names>MW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schmidt</surname>
                    <given-names>MK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nevanlinna</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tommiska</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aittom&#x000e4;ki</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pruntel</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Verhoef</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Van't Veer</surname>
                    <given-names>LJ</given-names>
                  </name>
                </person-group>
                <article-title>The single-nucleotide polymorphism 309 in the MDM2 gene contributes to the Li-Fraumeni syndrome and related phenotypes.</article-title>
                <source>Eur J Hum Genet.</source>
                <year>2007</year>
                <month>Jan</month>
                <volume>15</volume>
                <fpage>110</fpage>
                <lpage>4</lpage>
                <pub-id pub-id-type="pmid">17003841</pub-id>
              </element-citation>
            </ref>
            <ref id="li-fraumeni.REF.ruijs.2010.421">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ruijs</surname>
                    <given-names>MW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Verhoef</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rookus</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pruntel</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van der Hout</surname>
                    <given-names>AH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hagervorst</surname>
                    <given-names>EB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kluijt</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sijmons</surname>
                    <given-names>RH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aalfs</surname>
                    <given-names>CM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wagner</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ausems</surname>
                    <given-names>MG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hoogerbrugge</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van Asperen</surname>
                    <given-names>CJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gomez Garcia</surname>
                    <given-names>EB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Meijers-Heijboer</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ten Kate</surname>
                    <given-names>LP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Menko</surname>
                    <given-names>FH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van&#x02019;t Veer</surname>
                    <given-names>LJ</given-names>
                  </name>
                </person-group>
                <year>2010</year>
                <article-title>TP53 germline mutation testing in 180 families suspected of Li-Fraumeni syndrome: Mutation detection rate and relative frequency of cancers in different familial phenotypes.</article-title>
                <source>J Med Genet</source>
                <volume>47</volume>
                <fpage>421</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">20522432</pub-id>
              </element-citation>
            </ref>
            <ref id="li-fraumeni.REF.schneider.2004.222">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Schneider</surname>
                    <given-names>KA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>DiGianni</surname>
                    <given-names>LM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Patenaude</surname>
                    <given-names>AF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Klar</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stopfer</surname>
                    <given-names>JE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Calzone</surname>
                    <given-names>KA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Li</surname>
                    <given-names>FP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Weber</surname>
                    <given-names>BL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Garber</surname>
                    <given-names>JE</given-names>
                  </name>
                </person-group>
                <article-title>Accuracy of cancer family histories: comparison of two breast cancer syndromes.</article-title>
                <source>Genet Test.</source>
                <year>2004</year>
                <volume>8</volume>
                <fpage>222</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">15727243</pub-id>
              </element-citation>
            </ref>
            <ref id="li-fraumeni.REF.seidinger.2011.2228">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Seidinger</surname>
                    <given-names>AL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mastellaro</surname>
                    <given-names>MJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Paschoal Fortes</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Godoy Assumpcao</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aparecida Cardinalli</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aparecida Ganazza</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Correa Ribeiro</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brandalise</surname>
                    <given-names>SR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dos Santos Aguiar</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yunes</surname>
                    <given-names>JA</given-names>
                  </name>
                </person-group>
                <year>2011</year>
                <article-title>Association of the highly prevalent R337H mutation with pediatric choroid plexus carcinoma and osteosarcoma in southeast Brazil.</article-title>
                <source>Cancer</source>
                <volume>117</volume>
                <fpage>2228</fpage>
                <lpage>35</lpage>
                <pub-id pub-id-type="pmid">21192060</pub-id>
              </element-citation>
            </ref>
            <ref id="li-fraumeni.REF.shlien.2010.631">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Shlien</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Baskin</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Achatz</surname>
                    <given-names>MI</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stavropoulos</surname>
                    <given-names>DJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nichols</surname>
                    <given-names>KE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hudgins</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Morel</surname>
                    <given-names>CF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Adam</surname>
                    <given-names>MP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zhukova</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rotin</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Novokmet</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Druker</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shago</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ray</surname>
                    <given-names>PN</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hainaut</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Malkin</surname>
                    <given-names>D</given-names>
                  </name>
                </person-group>
                <article-title>A common molecular mechanism underlies two phenotypically distinct 17p13.1 microdeletion syndromes.</article-title>
                <source>Am J Hum Genet.</source>
                <year>2010</year>
                <volume>87</volume>
                <fpage>631</fpage>
                <lpage>42</lpage>
                <pub-id pub-id-type="pmid">21056402</pub-id>
              </element-citation>
            </ref>
            <ref id="li-fraumeni.REF.sidransky.1992.2984">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Sidransky</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tokino</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Helzlsouer</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zehnbauer</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rausch</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shelton</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Prestigiacomo</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vogelstein</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Davidson</surname>
                    <given-names>N</given-names>
                  </name>
                </person-group>
                <year>1992</year>
                <article-title>Inherited p53 gene mutations in breast cancer.</article-title>
                <source>Cancer Res</source>
                <volume>52</volume>
                <fpage>2984</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">1581912</pub-id>
              </element-citation>
            </ref>
            <ref id="li-fraumeni.REF.simpson.2005.87">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Simpson</surname>
                    <given-names>JL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Carson</surname>
                    <given-names>SA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cisneros</surname>
                    <given-names>P</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Preimplantation genetic diagnosis (PGD) for heritable neoplasia.</article-title>
                <source>J Natl Cancer Inst Monogr</source>
                <issue>34</issue>
                <fpage>87</fpage>
                <lpage>90</lpage>
                <pub-id pub-id-type="pmid">15784832</pub-id>
              </element-citation>
            </ref>
            <ref id="li-fraumeni.REF.sugawara.2011.535">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Sugawara</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Arai</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kasai</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fujiwara</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Haruta</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hosaka</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nkshida</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kurosumi</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kobayashi</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Akagi</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kaneko</surname>
                    <given-names>Y</given-names>
                  </name>
                </person-group>
                <year>2011</year>
                <article-title>Association of germline or somatic TP53 missense mutation with oncogene amplification in tumors developed in patients with Li-Fraumeni or Li-Fraumeni-like syndrome.</article-title>
                <source>Genes Chromosomes Cancer</source>
                <volume>50</volume>
                <fpage>535</fpage>
                <lpage>45</lpage>
                <pub-id pub-id-type="pmid">21484931</pub-id>
              </element-citation>
            </ref>
            <ref id="li-fraumeni.REF.tabori.2007.1415">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Tabori</surname>
                    <given-names>U</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nanda</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Druker</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lees</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Malkin</surname>
                    <given-names>D</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>Younger age of cancer initiation is associated with shorter telomere length in Li-Fraumeni syndrome.</article-title>
                <source>Cancer Res</source>
                <volume>67</volume>
                <fpage>1415</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">17308077</pub-id>
              </element-citation>
            </ref>
            <ref id="li-fraumeni.REF.tabori.2010.1995">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Tabori</surname>
                    <given-names>U</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shlien</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Baskin</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Levitt</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ray</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Alon</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hawkins</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bouffet</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pienkowska</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lafay-Cousin</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gozali</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zhukova</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shane</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gonzalez</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Finlay</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Malkin</surname>
                    <given-names>D</given-names>
                  </name>
                </person-group>
                <year>2010</year>
                <article-title>TP53 alterations determine clinical subgroups and survival of patients with choroid plexus tumors.</article-title>
                <source>J Clin Oncol</source>
                <volume>28</volume>
                <fpage>1995</fpage>
                <lpage>2001</lpage>
                <pub-id pub-id-type="pmid">20308654</pub-id>
              </element-citation>
            </ref>
            <ref id="li-fraumeni.REF.talwalkar.2010.1010">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Talwalkar</surname>
                    <given-names>SS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yin</surname>
                    <given-names>CC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Naeem</surname>
                    <given-names>RC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hicks</surname>
                    <given-names>MJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Strong</surname>
                    <given-names>LC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Abruzzo</surname>
                    <given-names>LV</given-names>
                  </name>
                </person-group>
                <year>2010</year>
                <article-title>Myelodysplastic syndromes arising in patients with germline TP53 mutation and Li-Fraumeni syndrome. (2010).</article-title>
                <source>Arch Pathol Lab Med</source>
                <volume>134</volume>
                <fpage>1010</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">20586629</pub-id>
              </element-citation>
            </ref>
            <ref id="li-fraumeni.REF.tan.2008.254">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Tan</surname>
                    <given-names>TY</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Orme</surname>
                    <given-names>LM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lynch</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Croxford</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dow</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dewan</surname>
                    <given-names>PA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lipton</surname>
                    <given-names>L</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>Biallelic PMS2 mutations and a distinctive childhood cancer syndrome.</article-title>
                <source>J Pediatr Hematol Oncol</source>
                <volume>30</volume>
                <fpage>254</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">18376293</pub-id>
              </element-citation>
            </ref>
            <ref id="li-fraumeni.REF.thull.2004.13">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Thull</surname>
                    <given-names>DL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vogel</surname>
                    <given-names>VG</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Recognition and management of hereditary breast cancer syndromes.</article-title>
                <source>Oncologist</source>
                <volume>9</volume>
                <fpage>13</fpage>
                <lpage>24</lpage>
                <pub-id pub-id-type="pmid">14755011</pub-id>
              </element-citation>
            </ref>
            <ref id="li-fraumeni.REF.tinat.2009.e108">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Tinat</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bougeard</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Baert-Desurmont</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vasseur</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Martin</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bouvignies</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Caron</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bressac-de Paillerets</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Berthet</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dugast</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bonaiti-Pellie</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stoppa-Lyonnet</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Frebourg</surname>
                    <given-names>T</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>2009 Version of the Chompret criteria for Li Fraumeni syndrome.</article-title>
                <source>J Clin Oncol</source>
                <volume>27</volume>
                <fpage>e108</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">19652052</pub-id>
              </element-citation>
            </ref>
            <ref id="li-fraumeni.REF.tomkova.2008.177">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Tomkova</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tomka</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zajac</surname>
                    <given-names>V</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>Contribution of p53, p63, and p73 to the developmental diseases and cancer.</article-title>
                <source>Neoplasma</source>
                <volume>55</volume>
                <fpage>177</fpage>
                <lpage>81</lpage>
                <pub-id pub-id-type="pmid">18348649</pub-id>
              </element-citation>
            </ref>
            <ref id="li-fraumeni.REF.trkova.2007.694">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Trkova</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Prochazkova</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Krutilkova</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sumerauer</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sedlacek</surname>
                    <given-names>Z</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>Telomere length in peripheral blood cells of germline TP53 mutation carriers is shorter than that of normal individuals of corresponding age.</article-title>
                <source>Cancer</source>
                <volume>110</volume>
                <fpage>694</fpage>
                <lpage>702</lpage>
                <pub-id pub-id-type="pmid">17567834</pub-id>
              </element-citation>
            </ref>
            <ref id="li-fraumeni.REF.varley.2003.313">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Varley</surname>
                    <given-names>JM</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>Germline TP53 mutations and Li-Fraumeni syndrome.</article-title>
                <source>Hum Mutat</source>
                <volume>21</volume>
                <fpage>313</fpage>
                <lpage>20</lpage>
                <pub-id pub-id-type="pmid">12619118</pub-id>
              </element-citation>
            </ref>
            <ref id="li-fraumeni.REF.varley.1997.1">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Varley</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Evans</surname>
                    <given-names>DG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Birch</surname>
                    <given-names>JM</given-names>
                  </name>
                </person-group>
                <year>1997</year>
                <article-title>Li-Fraumeni syndrome: a molecular and cinical review.</article-title>
                <source>BR J Cancer</source>
                <volume>76</volume>
                <fpage>1</fpage>
                <lpage>14</lpage>
                <pub-id pub-id-type="pmid">9218725</pub-id>
              </element-citation>
            </ref>
            <ref id="li-fraumeni.REF.varley.1999.995">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Varley</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McGown</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Thorncroft</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>James</surname>
                    <given-names>LA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Margison</surname>
                    <given-names>GP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Forster</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Evans</surname>
                    <given-names>DG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Harris</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kelsey</surname>
                    <given-names>AM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Birch</surname>
                    <given-names>JM</given-names>
                  </name>
                </person-group>
                <year>1999</year>
                <article-title>Are there low-penetrance TP53 Alleles? Evidence from childhood adrenocortical tumors.</article-title>
                <source>Am J Hum Genet</source>
                <volume>65</volume>
                <fpage>995</fpage>
                <lpage>1006</lpage>
                <pub-id pub-id-type="pmid">10486318</pub-id>
              </element-citation>
            </ref>
            <ref id="li-fraumeni.REF.villani.2011.559">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Villani</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tabori</surname>
                    <given-names>U</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schiffman</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shlien</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Beyene</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Druker</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Novokmet</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Finlay</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Malkin</surname>
                    <given-names>D</given-names>
                  </name>
                </person-group>
                <year>2011</year>
                <article-title>Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: A prospective observational study.</article-title>
                <source>Lancet Oncol</source>
                <volume>12</volume>
                <fpage>559</fpage>
                <lpage>67</lpage>
                <pub-id pub-id-type="pmid">21601526</pub-id>
              </element-citation>
            </ref>
            <ref id="li-fraumeni.REF.waldmann.2012.209">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Waldmann</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Patsalis</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fendrich</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Langer</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Saeger</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chaloupka</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ramaswamy</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fassnacht</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bartsch</surname>
                    <given-names>DK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Slater</surname>
                    <given-names>EP</given-names>
                  </name>
                </person-group>
                <year>2012</year>
                <article-title>Clinical impact of TP53 alterations in adrenocortical carcinomas.</article-title>
                <source>Langenbecks Arch Surg</source>
                <volume>397</volume>
                <fpage>209</fpage>
                <lpage>16</lpage>
                <pub-id pub-id-type="pmid">22203015</pub-id>
              </element-citation>
            </ref>
            <ref id="li-fraumeni.REF.walsh.2006.1379">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Walsh</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Casadei</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Coats</surname>
                    <given-names>KH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Swisher</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stray</surname>
                    <given-names>SM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Higgins</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Roach</surname>
                    <given-names>KC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mandell</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lee</surname>
                    <given-names>MK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ciernikova</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Foretova</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Soucek</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>King</surname>
                    <given-names>MC</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer.</article-title>
                <source>JAMA</source>
                <volume>295</volume>
                <fpage>1379</fpage>
                <lpage>88</lpage>
                <pub-id pub-id-type="pmid">16551709</pub-id>
              </element-citation>
            </ref>
            <ref id="li-fraumeni.REF.wang.2003.483">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Wang</surname>
                    <given-names>QE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Xhu</surname>
                    <given-names>Q</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wani</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wani</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chen</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wani</surname>
                    <given-names>AA</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>Tumor suppressor p53 dependent recruitment of nucleotide excision repair factors XPC and TFIIH to DNA damage.</article-title>
                <source>DNA Repair (Amst)</source>
                <volume>2</volume>
                <fpage>483</fpage>
                <lpage>99</lpage>
                <pub-id pub-id-type="pmid">12713809</pub-id>
              </element-citation>
            </ref>
            <ref id="li-fraumeni.REF.wilson.2010.771">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Wilson</surname>
                    <given-names>JR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bateman</surname>
                    <given-names>AC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hanson</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>An</surname>
                    <given-names>Q</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Evans</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rahman</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jones</surname>
                    <given-names>JL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eccles</surname>
                    <given-names>DM</given-names>
                  </name>
                </person-group>
                <year>2010</year>
                <article-title>A novel HER2-positive breast cancer phenotype arising from TP53 germline mutations.</article-title>
                <source>J Med Genet</source>
                <volume>47</volume>
                <fpage>771</fpage>
                <lpage>4</lpage>
                <pub-id pub-id-type="pmid">20805372</pub-id>
              </element-citation>
            </ref>
            <ref id="li-fraumeni.REF.wong.2006.73">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Wong</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Verselis</surname>
                    <given-names>SJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Garber</surname>
                    <given-names>JE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schneider</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>DiGianni</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stockwell</surname>
                    <given-names>DH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Li</surname>
                    <given-names>FP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Syngal</surname>
                    <given-names>S</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Prevalence of early onset colorectal cancer in 397 patients with classic Li-Fraumeni syndrome.</article-title>
                <source>Gastroenterology</source>
                <volume>130</volume>
                <fpage>73</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">16401470</pub-id>
              </element-citation>
            </ref>
            <ref id="li-fraumeni.REF.wu.2011.663">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Wu</surname>
                    <given-names>CC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Krahe</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lozano</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zhang</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wilson</surname>
                    <given-names>CD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jo</surname>
                    <given-names>EJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Amos</surname>
                    <given-names>CI</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shete</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Strong</surname>
                    <given-names>LC</given-names>
                  </name>
                </person-group>
                <year>2011</year>
                <article-title>Joint effects of germ-line TP53 mutation, MDM2 SNP309, and gender on cancer risk in family studies of Li-Fraumeni syndrome.</article-title>
                <source>Hum Genet</source>
                <volume>129</volume>
                <fpage>663</fpage>
                <lpage>73</lpage>
                <pub-id pub-id-type="pmid">21305319</pub-id>
              </element-citation>
            </ref>
            <ref id="li-fraumeni.REF.wu.2006.8287">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Wu</surname>
                    <given-names>CC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shete</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Amos</surname>
                    <given-names>CI</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Strong</surname>
                    <given-names>LC</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Joint effects of germ-line p53 mutation and sex on cancer risk in Li-Fraumeni syndrome.</article-title>
                <source>Cancer Res</source>
                <volume>66</volume>
                <fpage>8287</fpage>
                <lpage>92</lpage>
                <pub-id pub-id-type="pmid">16912210</pub-id>
              </element-citation>
            </ref>
            <ref id="li-fraumeni.REF.yamada.2009.973">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Yamada</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shinmura</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yamamura</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kurachi</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nakamura</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tsuneyoshi</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yokota</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Maekawa</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sugimura</surname>
                    <given-names>H</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>Identification and characterization of a novel germline p53 mutation in a patient with glioblastoma and colon cancer.</article-title>
                <source>Int J Cancer</source>
                <volume>125</volume>
                <fpage>973</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">19405127</pub-id>
              </element-citation>
            </ref>
            <ref id="li-fraumeni.REF.yoshida.2012.444">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Yoshida</surname>
                    <given-names>GJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fuchimoto</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Osumi</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shimada</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hosaka</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Morioka</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mukai</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Masugi</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sakamoto</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kuroda</surname>
                    <given-names>T</given-names>
                  </name>
                </person-group>
                <year>2012</year>
                <article-title>Li-Fraumeni syndrome wtih simultaneous osteosarcoma and liver cancer: Increased expression of a CD44 variant isoform after chemotherapy.</article-title>
                <source>BMC Cancer</source>
                <volume>12</volume>
                <fpage>444</fpage>
                <pub-id pub-id-type="pmid">23031740</pub-id>
              </element-citation>
            </ref>
          </ref-list>
        </sec>
        <sec id="li-fraumeni.Suggested_Reading">
          <title>Suggested Reading</title>
          <ref-list id="li-fraumeni.Suggested_Reading.reflist0">
            <ref id="li-fraumeni.REF.the_chek2_breast_cancer_casecontrol_consortium.2004.1175">
              <element-citation publication-type="journal">
                <person-group>
                  <collab>The CHEK2 Breast Cancer Case-Control Consortium</collab>
                </person-group>
                <year>2004</year>
                <article-title>CHECK2*1100delC and susceptibility to breast cancer: A collaborative analysis involving 10,860 breast cancer cases and 9,065 controls from 10 studies.</article-title>
                <source>Am J Hum Genet</source>
                <volume>74</volume>
                <fpage>1175</fpage>
                <lpage>82</lpage>
                <pub-id pub-id-type="pmid">15122511</pub-id>
              </element-citation>
            </ref>
            <ref id="li-fraumeni.REF.varley.2000">
              <mixed-citation publication-type="webpage">Varley JM. Li-Fraumeni syndrome. <italic toggle="yes">Atlas of Genetics and Cytogenetics in Oncology and Haematology</italic>. Available <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://atlasgeneticsoncology.org/Kprones/LiFraumeniID10011.html">online</ext-link>. 2000. Accessed 6-23-16.</mixed-citation>
            </ref>
          </ref-list>
        </sec>
      </sec>
      <sec id="li-fraumeni.Chapter_Notes">
        <title>Chapter Notes</title>
        <sec id="li-fraumeni.Acknowledgments">
          <title>Acknowledgments</title>
          <p>We wish to acknowledge Dr Frederick P Li for his contributions and mentorship.</p>
        </sec>
        <sec id="li-fraumeni.Author_History">
          <title>Author History</title>
          <p>Judy Garber, MD, MPH (2010-present)Frederick P Li, MD; Dana Farber Cancer Institute (1998-2010)Kim E Nichols, MD (2013-present)Katherine A Schneider, MPH (1998-present)Kristin Zelley, MS (2013-present)</p>
        </sec>
        <sec id="li-fraumeni.Revision_History">
          <title>Revision History</title>
          <list list-type="bullet">
            <list-item>
              <p>11 April 2013 (me) Comprehensive update posted live</p>
            </list-item>
            <list-item>
              <p>9 February 2010 (me) Comprehensive update posted live</p>
            </list-item>
            <list-item>
              <p>12 October 2004 (me) Comprehensive update posted to live Web site</p>
            </list-item>
            <list-item>
              <p>3 October 2002 (me) Comprehensive update posted to live Web site</p>
            </list-item>
            <list-item>
              <p>19 January 1999 (me) Review posted to live Web site</p>
            </list-item>
            <list-item>
              <p>24 July 1998 (ks) Original submission</p>
            </list-item>
          </list>
        </sec>
      </sec>
    </body>
  </book-part>
</book-part-wrapper>
